


## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>7</sup> : <b>C07D 211/34, 417/04, 401/04, 265/30, A61K 31/445, 31/426</b>		<b>A1</b>	(11) International Publication Number: <b>WO 00/39091</b> (43) International Publication Date: <b>6 July 2000 (06.07.00)</b>
(21) International Application Number: <b>PCT/IB99/01914</b> (22) International Filing Date: <b>1 December 1999 (01.12.99)</b> (30) Priority Data: <b>60/114,091</b> <b>29 December 1998 (29.12.98)</b> <b>US</b> (71) Applicant (for all designated States except US): <b>PFIZER PRODUCTS INC. [US/US]; Eastern Point Road, Groton, CT 06340 (US).</b> (72) Inventors; and (75) Inventors/Applicants (for US only): <b>LIRAS, Spiros [GR/US]; 12 Kidds Way, Stonington, CT 06378 (US). ALLEN, Martin, Patrick [US/US]; 63 Mystic Road, North Stonington, CT 06359 (US). SEGELSTEIN, Barbara; Eileen [US/US]; 16 Woodland Lane, Gales Ferry, CT 06335 (US).</b> (74) Agents: <b>SPIEGEL, Allen, J. et al.; Simpson, Alison, Urquhart-Dykes &amp; Lord, Urquhart-Dykes &amp; Lord, 30 Welbeck Street, London W1M 7PG (GB).</b>			(81) Designated States: <b>AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</b>  <b>Published</b> <i>With international search report.</i>

(54) Title: **3,3-BIARYLPIPERIDINE AND 2,2-BIARYLMORPHOLINE DERIVATIVES**

## (57) Abstract

The present invention relates to compounds of formula (I), wherein Z<sup>1</sup>, Z<sup>2</sup>, X, Q, R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> are defined as in the specification, pharmaceutical compositions containing such compounds, the use of such compounds to treat neurological and gastrointestinal disorders.

BEST AVAILABLE COPY

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

5

3,3-BIARYLPIPERIDINE AND 2,2-BIARYLMORPHOLINE DERIVATIVESBackground of the Invention

This invention relates to 3,3-biarylpiiperidine and 2,2-biarylmorpholine derivatives which have utility as ligands for opioid receptors.

10 In the study of opioid biochemistry, a variety of endogenous opioid compounds and non-endogenous opioid compounds has been identified. In this effort, significant research has been focused on understanding the mechanism of opioid drug action, particularly as it relates to cellular and differentiated tissue opioid receptors.

Opioid drugs are typically classified by their binding selectivity in respect of the cellular and differentiated tissue receptors to which a specific drug species binds as a ligand. These  
15 receptors include mu ( $\mu$ ), delta ( $\delta$ ) and kappa ( $\kappa$ ) receptors.

At least three subtypes of opioid receptors (mu, delta and kappa) are described and documented in the scientific literature. All three receptors are present in the central and peripheral nervous systems of many species including man. Activation of delta receptors produces antinociception in rodents and can induce analgesia in man, in addition to influencing  
20 motility of the gastrointestinal tract. (See Burks, T.F. (1995) in "The Pharmacology of Opioid Peptides", edited by Tseng, L.F., Harwood Academic Publishers).

The well known narcotic opiates such as morphine and its analogs are selective for the opioid mu receptor. Mu receptors mediate analgesia, respiratory depression, and inhibition of gastrointestinal transit. Kappa receptors mediate analgesia and sedation.

25 The existence of the opioid delta receptor is a relatively recent discovery which followed the isolation and characterization of endogenous enkephalin peptides, which are ligands for the delta receptor. Research in the past decade has produced significant information about the delta receptor, but a clear picture of its function has not yet emerged. Delta receptors mediate analgesia, but do not appear to inhibit intestinal transit in the manner  
30 characteristic of mu receptors.

U.S. Patent 4,816,586, which issued on March 28, 1989 to P. S. Portoghese, refers to various delta opioid receptor antagonists. These compounds are described as possessing a unique opioid receptor antagonist profile, and include compounds that are highly selective for the delta opioid receptor.

35 U.S. Patent 4,518,711, which issued May 21, 1985 to V. J. Hruby *et al.*, describes cyclic, conformationally constrained analogs of enkephalins. These compounds include both agonists and antagonists for the delta receptor, and are said to induce pharmacological and therapeutic effects, such as analgesia in the case of agonist species of such compounds. The antagonist species of the disclosed compounds are suggested to be useful in the treatment of  
40 schizophrenia, Alzheimer's disease, and respiratory and cardiovascular functions.

5 S. Goenechea, *et al*, in "Investigation of the Biotransformation of Meclozine in the Human Body," *J. Clin. Chem. Clin. Biochem.*, 1988, 26(2), 105-15, describe the oral administration of a polyaryl piperazine compound in a study of meclozine metabolism in human subjects.

10 In "Plasma Levels, Biotransformation and Excretion of Oxatomide in Rats, Dogs, and Man," *Xenobiotica*, 1984, 15(6), 445-62, Meuldermans, W., *et al*. refer to a metabolic study of plasma levels, biotransformation, and excretion of oxatomide.

T. Iwamoto, *et al*, in "Effects of KB-2796, A New Calcium Antagonist, and Other Diphenylpiperazines on [<sup>3</sup>H]nitrendipine Binding", *Jpn. J. Pharmacol.*, 1988, 48(2), 241-7, describe the effect of a polyaryl piperazine as a calcium antagonist.

15 K. Natsuka, *et al*, in "Synthesis and Structure-Activity Relationships of 1-Substituted 4-(1,2-Diphenylethyl)piperazine Derivatives Having Narcotic Agonist and Antagonist Activity," *J. Med. Chem.*, 1987, 30 (10), 1779-1787, disclose racemates and enantiomers of 1-substituted 4-[2-(3-hydroxyphenyl)-1-phenylethyl]piperazine derivatives.

20 European Patent Application No. 458,160, published on November 27, 1991, refers to certain substituted diphenylmethane derivatives as analgesic and antiinflammatory agents, including compounds wherein the methylene bridging group (linking the two phenyl moieties) is substituted on the methylene carbon with a piperidinyl or piperazinyl group.

25 South African Patent Application No. 8604522, which was published on December 12, 1986, refers to certain N-substituted arylalkyl and aryl-alkylene substituted amino-heterocyclic compounds, including piperidine derivatives, as cardiovascular, antihistamine, and anti-secretory agents.

European Patent Application No. 133,323, published on February 20, 1985, refers to certain diphenylmethyl piperazine compounds as non-sedative antihistamines.


30 There is a continuing need in the art for improved opioid compounds, particularly compounds which are free of addictive character and other adverse side effects of conventional opiates such as morphine and pethidine.

The present inventor has discovered a novel class of 3,3-biaryl piperidine and morpholine derivatives that are potent and selective delta opioid ligands and are useful for treatment of rejection in organ transplants and skin grafts, epilepsy, chronic pain, neurogenic pain, nonsomatic pain, stroke, cerebral ischemia, shock, head trauma, spinal cord trauma, brain edema, Hodgkin's disease, Sjogren's disease, systemic lupus erythematosus, gastrointestinal disorders such as gastritis, functional bowel disease, irritable bowel syndrome, functional diarrhoea, functional distention, nonulcerogenic dyspepsia and other disorders of motility or secretion, and emesis, acute pain, chronic pain, neurogenic pain, nonsomatic pain, 35 allergies, respiratory disorders such as asthma, cough and apnea, inflammatory disorders such as rheumatoid arthritis, osteoarthritis, psoriasis and inflammatory bowel disease, 40 urogenital tract disorders such as urinary incontinence, hypoxia (*e.g.*, perinatal hypoxia),

- 5 hypoglycemic neuronal damage, chemical dependencies and addictions (e.g., a dependency on, or addiction to opiates, benzodiazepines, cocaine, nicotine or ethanol), drug or alcohol withdrawal symptoms, and cerebral deficits subsequent to cardiac bypass surgery and grafting.

### Summary of the Invention

10 This invention relates to compounds of the formula



- wherein  $R^1$  is hydrogen,  $(C_0-C_8)$ alkoxy- $(C_1-C_8)$ alkyl-, wherein the total number of carbon atoms is eight or less, aryl, aryl- $(C_1-C_8)$ alkyl-, heteroaryl, heteroaryl- $(C_1-C_8)$ alkyl-, heterocyclic, heterocyclic- $(C_1-C_8)$ alkyl-,  $(C_3-C_7)$ cycloalkyl-, or  $(C_3-C_7)$ cycloalkyl- $(C_1-C_8)$ alkyl-,
- 15 wherein said aryl and the aryl moiety of said aryl- $(C_1-C_8)$ alkyl- are selected, independently, from phenyl and naphthyl, and wherein said heteroaryl and the heteroaryl moiety of said heteroaryl- $(C_1-C_8)$ alkyl- are selected, independently, from pyrazinyl, benzofuranyl, quinolyl, isoquinolyl, benzothienyl, isobenzofuryl, pyrazolyl, indolyl, isoindolyl, benzimidazolyl, purinyl, carbazolyl, 1,2,5-thiadiazolyl, quinazolinyl, pyridazinyl, pyrazinyl, cinnolyl, phthalazinyl,
- 20 quinoxalinyl, xanthinyl, hypoxanthinyl, pteridinyl, 5-azacytidinyl, 5-azauracil, triazolopyridinyl, imidazolopyridinyl, pyrrolopyrimidinyl, pyrazolopyrimidinyl, oxazolyl, oxadiazolyl, isoxazolyl, thiazolyl, isothiazolyl, furanyl, pyrazolyl, pyrrolyl, tetrazolyl, triazolyl, thienyl, imidazolyl, pyridinyl, and pyrimidinyl; and wherein said heterocyclic and the heterocyclic moiety of said heterocyclic- $(C_1-C_8)$ alkyl- are selected from saturated or unsaturated nonaromatic monocyclic or bicyclic
- 25 ring systems, wherein said monocyclic ring systems contain from four to seven ring carbon atoms, from one to three of which may optionally be replaced with O, N or S, and wherein said bicyclic ring systems contain from seven to twelve ring carbon atoms, from one to four of which may optionally be replaced with O, N or S; and wherein any of the aryl, heteroaryl or heterocyclic moieties of  $R^1$  may optionally be substituted with from one to three substituents,
- 30 preferably with one or two substituents, independently selected from halo (i.e., chloro, fluoro, bromo or iodo),  $(C_1-C_6)$ alkyl optionally substituted with from one to seven (preferably with from zero to four) fluorine atoms, phenyl, benzyl, hydroxy, acetyl, amino, cyano, nitro,  $(C_1-C_6)$ alkoxy,  $(C_1-C_6)$ alkylamino and  $[(C_1-C_6)alkyl]_2$ amino, and wherein any of the alkyl moieties in  $R^1$  (e.g., the alkyl moieties of alkyl, alkoxy or alkylamino groups) may optionally be substituted with from one
- 35 to seven (preferably with from zero to four) fluorine atoms;

5  $R^2$  is hydrogen, aryl, heteroaryl, heterocyclic,  $SO_2R^4$ ,  $COR^4$ ,  $CONR^5R^6$ ,  $COOR^4$ , or  $C(OH)R^5R^6$  wherein each of  $R^4$ ,  $R^5$  and  $R^6$  is defined, independently, as  $R^1$  is defined above, or  $R^5$  and  $R^6$ , together with the carbon or nitrogen to which they are both attached, form a three to seven membered saturated ring containing from zero to three heterocarbons selected, independently, from O, N and S, and wherein said aryl, heteroaryl, and heterocyclic  
 10 are defined as such terms are defined above in the definition of  $R^1$ , and wherein any of the aryl, heteroaryl and heterocyclic moieties of  $R^2$  may optionally be substituted with from one to three substituents, preferably with one or two substituents, independently selected from halo (i.e., chloro, fluoro, bromo or iodo),  $(C_1-C_6)$ alkyl optionally substituted with from one to seven (preferably with from zero to four) fluorine atoms, phenyl, benzyl, hydroxy, acetyl, amino, cyano, nitro,  $(C_1-C_6)$ alkoxy optionally substituted with from one to seven (preferably with from zero to four) fluorine atoms,  $(C_1-C_6)$ alkylamino and  $[(C_1-C_6)alkyl]_2$ amino;

$R^3$  is hydroxy,  $-NHSO_2R^7$ ,  $-C(OH)R^7R^8$ ,  $-OC(=O)R^7$ , fluorine or  $-CONHR^7$ , wherein  $R^7$  and  $R^8$  are the same or different and are selected from hydrogen,  $(C_1-C_4)$ alkyl,  $(C_1-C_4)$ alkoxy and  $(C_1-C_4)$ alkoxy- $(C_1-C_4)$ alkyl having a total of four or less carbon atoms, and wherein any of  
 20 the alkyl moieties of  $R^7$  and  $R^8$  may optionally be substituted with from one to seven (preferably with from zero to four) fluorine atoms;

Q is oxygen or  $CH_2$ ;

X is CH or N; and

$Z^1$  and  $Z^2$  are selected, independently, from hydrogen, halo and  $(C_1-C_5)$ alkyl;

25 with the proviso that there are no two adjacent ring oxygen atoms and no ring oxygen atom adjacent to either a ring nitrogen atom or a ring sulfur atom in any of the heterocyclic or heteroaryl moieties of formula I;


and the pharmaceutically acceptable salts of such compounds.

Preferred compounds of the formula I include those wherein Q is  $CH_2$ .

30 Other preferred compounds of the formula I are those wherein X is CH.

Other preferred compounds of the formula I are those wherein  $R^3$  is OH,  $CONH_2$ , or fluoro.


Other preferred compounds of the formula I are those wherein  $R^2$  is selected from  $C(OH)(C_2H_5)_2$ ,  $CON(C_2H_5)_2$ ,  $CONCH_3(C_2H_5)$  and the following cyclic groups:



35

Other preferred compounds of the formula I are those wherein  $Z^1$  and  $Z^2$  are selected, independently, from hydrogen and fluorine.

- 5 Other preferred compounds of the formula I are those wherein R<sup>1</sup> is selected from allyl, cyclopropylmethyl, methyl, 2,2,2-trifluoroethyl, methallyl, isopropyl, 2-pyridinyl, 2-pyrimidinyl and



- Examples of other embodiments of the present invention are the following:
- 10 compounds of the formula I wherein Q is oxygen and X is CH;  
 compounds of the formula I wherein Q is oxygen and X is N;  
 compounds of the formula I wherein Q is oxygen, X is CH and R<sup>3</sup> is OH, CONH<sub>2</sub>, or fluoro;  
 compounds of the formula I wherein Q is oxygen and X is N;  
 15 compounds of the formula I wherein Q is CH<sub>2</sub>, X is N, and R<sup>3</sup> is OH, CONH<sub>2</sub>, or fluoro;  
 compounds of the formula I wherein Q is CH<sub>2</sub>, X is N, R<sup>3</sup> is OH, CONH<sub>2</sub>, or fluoro, and R<sup>2</sup> is selected from C(OH)(C<sub>2</sub>H<sub>5</sub>)<sub>2</sub>, CON(C<sub>2</sub>H<sub>5</sub>)<sub>2</sub> and one of cyclic groups (a) - (f) depicted above; and  
 compounds of the formula I wherein Q is oxygen, X is CH, and R<sup>3</sup> is OH, CONH<sub>2</sub>, or fluoro;  
 20 fluoro;  
 compounds of the formula I wherein Q is oxygen, X is NH, R<sup>3</sup> is OH, CONH<sub>2</sub>, or fluoro, and R<sup>2</sup> is selected from C(OH)(C<sub>2</sub>H<sub>5</sub>)<sub>2</sub>, CON(C<sub>2</sub>H<sub>5</sub>)<sub>2</sub> and one of cyclic groups (a) - (f) depicted above;  
 compounds of the formula I wherein Q is oxygen, X is CH, R<sup>3</sup> is OH, CONH<sub>2</sub> or fluoro,  
 25 Z<sup>1</sup> and Z<sup>2</sup> or selected, independently, from hydrogen and fluoro, and R<sup>1</sup> is selected from allyl, cyclopropylmethyl, methyl, methallyl, isopropyl, 2-pyridinyl, 2-pyrimidinyl and cyclic group (g) depicted above; and  
 compounds of the formula I wherein Q is oxygen, X is NH, R<sup>3</sup> is OH, CONH<sub>2</sub> or fluoro, Z<sup>1</sup> and Z<sup>2</sup> or selected, independently, from hydrogen and fluoro, and R<sup>1</sup> is selected from allyl, cyclopropylmethyl, methyl, methallyl, isopropyl, 2-pyridinyl, 2-pyrimidinyl and cyclic group (g) depicted above.  
 30

The compounds of formula I and their pharmaceutically acceptable salts are opioid receptor ligands and are useful in the treatment of a variety of neurological and gastrointestinal disorders. Examples of disorders that can be treated with the compounds of formula I and their pharmaceutically acceptable salts are rejection in organ transplants and skin grafts, epilepsy, chronic pain, neurogenic pain, nonsomatic pain, stroke, cerebral ischemia, shock, head trauma, spinal cord trauma, brain edema, Hodgkin's disease, Sjogren's disease, systemic lupus erythematosus, gastrointestinal disorders such as gastritis, functional bowel disease, irritable bowel syndrome, functional diarrhoea, functional distention,

5 nonulcerogenic dyspepsia and other disorders of motility or secretion, and emesis, acute pain, chronic pain, neurogenic pain, nonsomatic pain, allergies, respiratory disorders such as asthma, cough and apnea, inflammatory disorders such as rheumatoid arthritis, osteoarthritis, psoriasis and inflammatory bowel disease, urogenital tract disorders such as urinary incontinence, hypoxia (e.g., perinatal hypoxia), hypoglycemic neuronal damage, chemical  
10 dependencies and addictions (e.g., a dependency on, or addiction to opiates, benzodiazepines, cocaine, nicotine or ethanol), drug or alcohol withdrawal symptoms, and cerebral deficits subsequent to cardiac bypass surgery and grafting.

The present invention also relates to the pharmaceutically acceptable acid addition and base addition salts of compounds of the formula I. The acids which are used to prepare the  
15 pharmaceutically acceptable acid addition salts of the aforementioned base compounds of this invention are those which form non-toxic acid addition salts, i.e., salts containing pharmacologically acceptable anions, such as the hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, acetate, lactate, citrate, acid citrate, tartrate, bitartrate, succinate, maleate, fumarate, gluconate, saccharate, benzoate,  
20 methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate and pamoate [i.e., 1,1'-methylene-bis-(2-hydroxy-3-naphthoate)]salts. The chemical bases that are used as reagents to prepare the pharmaceutically acceptable base salts of this invention are those which form non-toxic base salts with the acidic compounds of formula I. Such non-toxic base salts include those derived from such pharmacologically acceptable cations as sodium, potassium,  
25 calcium and magnesium, etc.

The present invention also relates to the pharmaceutically acceptable base addition salts of compounds of the formula I. These salts are all prepared by conventional techniques. The chemical bases that are used as reagents to prepare the pharmaceutically acceptable base salts of this invention are those which form non-toxic base salts with the acidic compounds of formula  
30 I. Such non-toxic base salts include those derived from such pharmacologically acceptable cations as sodium, potassium, calcium and magnesium, etc.

For a review on pharmaceutically acceptable salts, see Berge et al., J. Pharm. Sci., 66, 1-19 (1977).

This invention also relates to a pharmaceutical composition for treating a disorder or  
35 condition, the treatment or prevention of which can be effected or facilitated by modulating (i.e., increasing or decreasing) binding to opioid receptors in a mammal, including a human, comprising an amount of a compound of the formula I, or a pharmaceutically effective salt thereof, that is effective in treating such disorder or condition and a pharmaceutically acceptable carrier.

40 This invention also relates to a method of treating a disorder or condition, the treatment of which can be effected or facilitated by modulating binding to opioid receptors in a mammal, comprising administering to a mammal in need of such treatment an amount of a compound of



5 the formula I, or a pharmaceutically effective salt thereof, that is effective in treating such disorder or condition.

This invention also relates to a pharmaceutical composition for treating a disorder or condition selected from inflammatory diseases such as arthritis (e.g., rheumatoid arthritis and osteoarthritis), psoriasis, asthma, or inflammatory bowel disease, disorders of respiratory  
10 function such as asthma, cough and apnea, allergies, gastrointestinal disorders such as gastritis, functional bowel disease, irritable bowel syndrome, functional diarrhoea, functional distension, functional pain, nonulcerogenic dyspepsia and other disorders of motility or secretion, and emesis, stroke, shock, brain edema, head trauma, spinal cord trauma, cerebral ischemia, cerebral deficits subsequent to cardiac bypass surgery and grafting, urogenital tract disorders  
15 such as urinary incontinence, chemical dependencies and addictions (e.g., addictions to or dependencies on alcohol, opiates, benzodiazepines, nicotine, heroin or cocaine), chronic pain, nonsomatic pain, acute pain and neurogenic pain, systemic lupus erythematosus, Hodgkin's disease, Sjogren's disease, epilepsy and rejection in organ transplants and skin grafts in a mammal, including a human, comprising a glutamate neurotransmission modulating effective  
20 amount of a compound of the formula I, or a pharmaceutically salt thereof, and a pharmaceutically acceptable carrier.

This invention also relates to a method for treating a condition selected from inflammatory diseases such as arthritis, psoriasis, asthma, or inflammatory bowel disease, disorders of respiratory function such as asthma, cough and apnea, allergies, gastrointestinal  
25 disorders such as gastritis, functional bowel disease, irritable bowel syndrome, functional diarrhoea, functional distension, functional pain, nonulcerogenic dyspepsia and other disorders of motility or secretion, and emesis, stroke, shock, brain edema, head trauma, spinal cord trauma, cerebral ischemia, cerebral deficits subsequent to cardiac bypass surgery and grafting, urogenital tract disorders such as urinary incontinence, chemical dependencies and addictions  
30 (e.g., addictions to or dependencies on alcohol, opiates, benzodiazepines, nicotine, heroin or cocaine), chronic pain, nonsomatic pain, acute pain and neurogenic pain, systemic lupus erythematosus, Hodgkin's disease, Sjogren's disease, epilepsy and rejection in organ transplants and skin grafts, in a mammal, comprising administering to such mammal, including a human, an opioid receptor binding modulating effective amount of a compound of the formula I, or a  
35 pharmaceutically acceptable salt thereof.

This invention also relates to a pharmaceutical composition for treating a disorder or condition, the treatment of which can be effected or facilitated by modulating binding to opioid receptors in a mammal, including a human, comprising an opioid receptor binding modulating effective amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof,  
40 and a pharmaceutically acceptable carrier.

This invention also relates to a method for treating a disorder or condition, the treatment of which can be effected or facilitated by modulating in a mammal, including a human,

- 5 comprising administering to such mammal an opioid receptor binding modulating effective amount of a compound of the formula I or a pharmaceutically acceptable salt thereof.

This invention also relates to a method of treating a condition selected from inflammatory diseases such as arthritis, psoriasis, asthma, or inflammatory bowel disease, disorders of respiratory function such as asthma, cough and apnea, allergies, gastrointestinal disorders such as gastritis, functional bowel disease, irritable bowel syndrome, functional diarrhoea, functional distension, functional pain, nonulcerogenic dyspepsia and other disorders of motility or secretion, and emesis, stroke, shock, brain edema, head trauma, spinal cord trauma, cerebral ischemia, cerebral deficits subsequent to cardiac bypass surgery and grafting, urogenital tract disorders such as urinary incontinence, chemical dependencies and addictions (e.g., addictions to or dependencies on alcohol, opiates, benzodiazepines, nicotine, heroin or cocaine), chronic pain, nonsomatic pain, acute pain and neurogenic pain, systemic lupus erythematosus, Hodgkin's disease, Sjogren's disease, epilepsy and rejection in organ transplants and skin grafts in a mammal, comprising administering to a mammal in need of such treatment an amount of a compound of the formula I that is effective in treating such condition.

20 This invention also relates to a pharmaceutical composition for treating a condition selected from inflammatory diseases such as arthritis, psoriasis, asthma, or inflammatory bowel disease, disorders of respiratory function such as asthma, cough and apnea, allergies, gastrointestinal disorders such as gastritis, functional bowel disease, irritable bowel syndrome, functional diarrhoea, functional distension, functional pain, nonulcerogenic dyspepsia and other disorders of motility or secretion, and emesis, stroke, shock, brain edema, head trauma, spinal cord trauma, cerebral ischemia, cerebral deficits subsequent to cardiac bypass surgery and grafting, urogenital tract disorders such as urinary incontinence, chemical dependencies and addictions (e.g., addictions to or dependencies on alcohol, opiates, benzodiazepines, nicotine, heroin or cocaine), chronic pain, nonsomatic pain, acute pain and neurogenic pain, systemic lupus erythematosus, Hodgkin's disease, Sjogren's disease, epilepsy and rejection in organ transplants and skin grafts in a mammal, comprising an amount of a compound of the formula I that is effective in treating such condition and a pharmaceutically acceptable carrier.

Unless otherwise indicated, the alkyl groups referred to herein, as well as the alkyl moieties of other groups referred to herein (e.g., alkoxy), may be linear or branched, and they may also be cyclic (e.g., cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl) or be linear or branched and contain cyclic moieties.

The term "alkoxy", as used herein, means "-O-alkyl", wherein "alkyl" is defined as above.

The term "alkylene", as used herein, means an alkyl group having two available binding sites (i.e., -alkyl-, wherein alkyl is defined as above).

40 The term "treating" as used herein, refers to reversing, alleviating, inhibiting the progress of, or preventing the disorder or condition to which such term applies, or one or more symptoms

5 of such disorder or condition. The term "treatment", as used herein, refers to the act of treating, as "treating" is defined immediately above.

Unless otherwise indicated, "halo" and "halogen", as used herein, refer to fluorine, bromine, chlorine or iodine.

10 Compounds of the formula I may have chiral centers and therefore may exist in different enantiomeric and diastereomeric forms. This invention relates to all optical isomers and all other stereoisomers of compounds of the formula I, and to all racemic and other mixtures thereof, and to all pharmaceutical compositions and methods of treatment defined above that contain or employ such isomers or mixtures.

Formula I above also includes isotopically labelled compounds that are identical to  
15 those depicted in formula I, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine and chlorine, such as  $^2\text{H}$ ,  $^3\text{H}$ ,  $^{13}\text{C}$ ,  $^{14}\text{C}$ ,  $^{15}\text{N}$ ,  $^{18}\text{O}$ ,  $^{17}\text{O}$ ,  $^{31}\text{P}$ ,  $^{32}\text{P}$ ,  $^{35}\text{S}$ ,  $^{18}\text{F}$ , and  $^{36}\text{Cl}$ , respectively.  
20 Certain isotopically labelled compounds of the present invention, for example, those into which radioactive isotopes such as  $^3\text{H}$  and  $^{14}\text{C}$  are incorporated, are useful in drug and/or substrate tissue distribution assays. Tritiated, i.e.,  $^3\text{H}$ , and carbon-14, i.e.,  $^{14}\text{C}$ , isotopes are particularly preferred for their ease of preparation and detectability. Further, substitution with heavier isotopes such as deuterium, i.e.,  $^2\text{H}$ , can afford certain therapeutic advantages resulting from  
25 greater metabolic stability, for example, increased *in vivo* half-life or reduced dosage requirements and, hence, may be preferred in some circumstances. Isotopically labelled compounds of formula I of this invention can generally be prepared by carrying out the procedures disclosed in the schemes and/or in the Examples below, by substituting a readily available isotopically labelled reagent for a non-isotopically labelled reagent.

### 30 Detailed Description of the Invention

The compounds of formula I can be prepared according to the methods illustrated in Schemes 1-9 and discussed below. In the reaction schemes and discussion that follow, unless otherwise indicated, X, Q, Y, Z<sup>1</sup>, Z<sup>2</sup>, R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup> and R<sup>8</sup> and structural formula I are defined as above.

35 Scheme 1 illustrates a method for the preparation of compounds with the general formula I wherein R<sup>3</sup> is (C<sub>1</sub>-C<sub>6</sub>)alkoxy or fluorine, R<sup>2</sup> is CONR<sup>5</sup>R<sup>6</sup>, Y is carbon, Q is carbon, X is carbon and R<sup>1</sup> is as defined above with the proviso that it is not attached to the piperidine nitrogen at a secondary alkyl carbon or an aryl group. Referring to Scheme 1, a bromobenzene derivative of formula Q, wherein R<sup>3</sup> is methoxy or fluorine, is cooled to -70°C in  
40 dry tetrahydrofuran, and then a solution of n-butyllithium is added to it. The resulting solution

5 is then treated with N-benzylpiperidin-3-one and the solution is allowed to warm to room temperature to produce the corresponding compound of formula 1.

Alternatively, the benzene derivative of formula 0 in tetrahydrofuran can be treated with magnesium at a temperature from about 0°C to the reflux temperature, preferably starting at room temperature for about three hours and then heating to reflux and letting the reaction  
10 proceed for another hour, after which N-benzylpiperidin-3-one is added to the mixture. The resulting solution is then stirred at a temperature ranging from about 0°C to the reflux temperature, preferably at about room temperature, to produce the corresponding compound of formula 1.

The compound of formula 1, produced by either of the above methods, in  
15 dichloroethane is then treated with phenol and aluminum chloride or another Lewis acid (e.g., zinc chloride, boron trifluoride etherate), and the resulting solution is stirred at a temperature ranging from about 0°C to the reflux temperature, preferably at about the reflux temperature, to produce the corresponding phenol derivative of formula 2. The compound of formula 2 is then treated with trifluoromethane sulfonic anhydride or another suitable reagent such as N-  
20 phenyltrifluoromethanesulfonimide, in the presence of a base such as pyridine, triethylamine, another trialkyl amine, an alkali metal hydride or an alkali metal carbonate, to form the trifluoromethane sulfonate ester of formula 3. This reaction is typically performed in dichloromethane at a temperature ranging from about 0°C to the reflux temperature, preferably at about room temperature.


25 The compound of formula 3 is placed under a carbon monoxide atmosphere at a pressure ranging from about 14 to 100 psi, in a solution of dimethylsulfoxide and a lower alkanol such as methanol or ethanol, with a suitable trialkylamine base (e.g., triethylamine) and palladium acetate with 1,3-bis(diphenylphosphino)propane (DPPP), 1,3-bis(diphenylphosphino)-ferrocene (DPPF) or another suitable palladium ligand. Other suitable  
30 palladium catalysts such as bis(triphenylphosphine) palladium dichloride may also be used. This reaction is performed at temperatures ranging from about 20°C to 100°C.

Treatment of the ester of formula 4 with an aluminum amide of a primary or secondary amine, for example, diethyl amine, in a solvent such as dichloroethane or toluene, at a temperature ranging from about 20°C to about the reflux temperature, preferably at about  
35 the reflux temperature, yields the corresponding amide of formula 5. Variations in the nature of the R<sup>1</sup> group on the piperidine nitrogen can be effected in the following manner, as illustrated by process steps (5 → 6 → 7) in Scheme 1. The compound of formula 5 is placed under a hydrogen atmosphere at pressures ranging from about 14 to 100 psi, in ethanol or other another solvent such as acetic acid or methanol, to produce the corresponding  
40 compound of formula 6. This reaction is typically carried out at a temperature from about 0°C to about the reflux temperature, preferably at about room temperature.

- 5 Treatment of the compound of formula 6 with an aldehyde and sodium triacetoxyborohydride or another reducing agent (e.g., sodium borohydride or sodium cyanoborohydride), in dicloromethane, 1,2 dichloroethane or another suitable solvent such as methanol, ethanol or toluene, at a temperature ranging from about 0°C to 100°C, preferably at about room temperature, yields the desired compound of formula 7.


5

## SCHEME 1




5

## SCHEME 1 CONTINUED



- 5 Compounds of formula 1 wherein  $R^1$  is a group that attaches to the piperidine nitrogen via an aryl moiety or a primary or secondary alkyl moiety, can be prepared by treating the corresponding compound of formula 6 with an alkylating or arylating agent of the formula  $R^1X$ , wherein X is a leaving group such as chloro, bromo, iodo, triflate (OTf), mesylate (OMs) or tosylate (Ots), and sodium or potassium carbonate or another alkali metal carbonate or bicarbonate in a solvent such as dimethylformamide, dichloromethane or 1,2 dichloroethane, at a temperature ranging from about 20°C to 100°C, as shown below in Scheme 2.

SCHEME 2




- 15 Compounds of the general formula 1 where  $R^3$  is hydroxy can be prepared by deprotecting the corresponding alkyl ether of formula 7 (wherein  $R^{10}$  is  $(C_1-C_6)$ alkyl) with boron tribromide in dichloromethane, or with aqueous hydrobromic acid and acetic acid, or with sodium ethanethiolate in dimethylformamide, at a temperature ranging from about 0°C to the reflux temperature, as shown in Scheme 3. Room temperature is preferred when boron tribromide is used, the reflux temperature is preferred when hydrobromic acid/acetic acid is used, and about 100°C to about 120°C is preferred when sodium ethanmethiolate is used.



5


## SCHEME 3



The carboxamide of formula 12 can be obtained by conversion the phenol of formula 9 in to triflate ester of formula 10 with the addition of triflic anhydride in the presence of a base such as pyridine, or a trialkylamine base like triethylamine, and in the presence of dimethylamino pyridine in a solvent such as methylene chloride, at a temperature ranging from - 40°C to the reflux temperature, preferably at 0°C. The triflate ester of formula 10 is then converted into the nitrile of formula 11 by treatment with zinc cyanide and a palladium catalyst such as tetrakis triphenylphosphine palladium, in a solvent such as dimethylformamide, or toluene, at a temperature from about 0°C to about the reflux temperature, preferably at about the reflux temperature. The nitrile of formula 11 can be converted into the carboxamide of formula 12 by treatment with hydrogen peroxide and sodium carbonate in ethanol, at a temperature ranging from about 0°C to about the reflux temperature, preferably at about room temperature.


5

## SCHEME 4




Compounds of the general formula I wherein  $\text{R}^3$  is methoxy, hydroxy or fluorine and  $\text{R}^2$  is an aromatic or heteroaromatic moiety (referred to in Scheme 5 as compounds of the formula 14) can be prepared by organometallic coupling of a compound of the formula 3 with an aryl and heteroaryl boronic acid, wherein aryl and heteroaryl are defined as in the definitions of  $\text{R}^1$  and  $\text{R}^2$ , in a solvent such as ethanol or toluene, in the presence of a palladium catalyst such as tetrakis triphenylphosphine palladium and a trialkylamine base (e.g., triethylamine) or alkali metal carbonate base, as shown below in Scheme 5. This reaction is generally carried out at a temperature from about room temperature to about the reflux temperature, preferably at about the reflux temperature.

5

SCHEME 5


Compounds of the general formula 1 where R<sup>3</sup> is fluoro or methoxy and R<sup>2</sup> is a carbinol such as diethyl carbinol (referred to in Scheme 6 as compounds of the formula 15) can be prepared, as illustrated in Scheme 6 by treatment of the ester of formula 4 with an alkyl Grignard or alkyl lithium reagent, in a solvent such as ether or tetrahydrofuran, at a temperature ranging from about -78°C to about the reflux temperature, preferably starting at room temperature and heating to about the reflux temperature.

SCHEME 6

Compounds of the formulas 14 (Scheme 5) and 15 (Scheme 6) can be converted into the analogous compounds wherein R<sup>3</sup> = CONH<sub>2</sub> using the procedures illustrated in Schemes 3 and 4 and described above for synthesizing carboxamides of the formula 12.

Compounds of the general formula 16 can be prepared, as illustrated in Scheme 7, by treatment of the phenol of formula 9 with an acid chloride, in the presence of pyridine or a trialkylamine such as triethylamine in dichloromethane, tetrahydrofuran or another suitable solvent, at a temperature ranging from about -78°C to about the reflux temperature, preferably at room temperature.

SCHEME 7



5

Scheme 8 illustrates a method for preparing compounds of the general formula I wherein Q is oxygen, R<sup>3</sup> is methoxy, hydroxy, R<sup>2</sup> is CONR<sup>5</sup>R<sup>6</sup> and R<sup>1</sup> is as defined above. Referring to Scheme 8, a bromobenzene derivative of formula 17, wherein R<sup>3</sup> is methoxy or fluorine, is cooled to -70°C in dry tetrahydrofuran, and treated with a solution of n-butyllithium.

10 The resulting solution is then treated with an appropriately substituted aryl aldehyde of the formula 18, and the solution is allowed to warm to room temperature to produce the corresponding compound of formula 19.

Alternatively, the benzene derivative of formula 17 in tetrahydrofuran can be treated with magnesium at a temperature from about 0°C to about the reflux temperature, preferably

15 starting at room temperature for about three hours and then heating to reflux and letting the reaction proceed for about another hour, after which the aryl aldehyde of formula 18 is added to the mixture. The resulting solution is then stirred at a temperature ranging from about 0°C to the reflux temperature, preferably at about room temperature, to produce the corresponding compound of formula 19.

20 Compounds of the formula 20 can be prepared using a Swern oxidation. Thus, a solution of trifluoroacetic anhydride in methylene chloride is treated with DMSO at a temperature from about -78°C to about room temperature, preferably at -78°C, and to this mixture is added a solution of the compound of formula 19 in methylene chloride, followed by addition of a trialkylamine base such as triethylamine. The mixture is allowed to warm to room

25 temperature to produce the corresponding compound of the formula 20. Alternatively, compounds of the formula 20 can be prepared by oxidation of the compound of formula 19 by addition of pyridinium dichromate, in a solvent such as methylene chloride, at a temperature from about -78°C to about the reflux temperature, preferably at about room temperature.

Compounds of the formula 20 can be converted into compounds of formula 21 via

30 addition of trimethylsilyl cyanide in the presence of zinc iodide in a solvent such as methylene chloride, at a temperature from about -78°C to about the reflux temperature, preferably at about room temperature, followed by treatment of the intermediate cyanohydrine with lithium aluminum hydride or another metal hydride source such as diisobutyl aluminum hydride, in a

5 solvent such as methylene chloride, at a temperature from about -78°C to about the reflux temperature, preferably at 0°C.

Treatment of a compound of the formula 21 with a trialkylamine base such as triethylamine and chloroacetylchloride in a solvent such as toluene or tetrahydrofuran, at a temperature ranging from about -40°C to about the reflux temperature, preferably at 0°C,  
10 yields the corresponding compound having formula 22. Subsequent treatment of a dilute solution of the resulting compound of formula 22 in a solvent such as tetrahydrofuran or toluene with metal alkoxides, preferably potassium t-butoxide, at a temperature ranging from about -40°C to about the reflux temperature, preferably at about room temperature, affords the corresponding derivative of formula 23. Reaction of the derivative of formula 23 with  
15 lithium aluminum hydride or another metal hydride source such as dibutyl aluminum hydride, in a solvent such as methylene chloride, at a temperature from about -78°C to about the reflux temperature, preferably at about 0°C, affords the corresponding compound of formula 24.


When R<sup>1</sup> is not attached to the morpholine nitrogen at a secondary alkyl carbon or an aryl group, the R<sup>1</sup> group can be added to the morpholine nitrogen of the compound of formula  
20 24 by reacting such compound with an aldehyde and sodium triacetoxyborohydride or another reducing agent (e.g., sodium borohydride or sodium cyanoborohydride) in dichloromethane, 1,2 dichloroethane or another suitable solvent such as methanol, ethanol or toluene, at a temperature ranging from about 0°C to 100°C, preferably at about room temperature. This reaction yields the desired compound of formula 25. When R<sup>1</sup> is attached to the morpholine  
25 nitrogen via an aryl moiety or a primary or secondary alkyl moiety, it can be added to the compound of formula 24 using the procedure illustrated in Scheme 2 and described above. Compounds of the formula 25 can be produced by alkylation or heteroarylation of the corresponding compound of formula 24 using conditions identical to those described above for the preparation of compounds of the formula 7 Scheme 2.

30 The compound of formula 25 is then placed under a carbon monoxide atmosphere at a pressure ranging from about 14 to 100 psi, in a solution of dimethylsulfoxide and a lower alkanol such as methanol or ethanol, with a suitable trialkylamine base (e.g., triethylamine) and palladium acetate with 1,3-bis(diphenylphosphino)propane (DPPP) or another suitable palladium ligand, to yield the desired compound of formula 26. Other suitable palladium  
35 catalysts, such as bis(triphenylphosphine) palladium dichloride, may also be used. This reaction can be conducted at temperatures ranging from about 20°C to about 100°C, preferably at about 70°C. Treatment of the ester of formula 26 with an aluminum amide of a primary or secondary amine, for example, diethyl amine, in a solvent such as dichloroethane or toluene, at a temperature ranging from about 20°C to about the reflux temperature,  
40 preferably at about the reflux temperature, yields the corresponding amide of formula 27.

- 5           Compounds of the formula 28 where  $R^3$  is hydroxy can be prepared by deprotecting the corresponding alkyl ethers of formula 27 (wherein  $R^3$  is  $OR^{10}$  and  $R^{10}$  is  $(C_1-C_6)$ alkyl) with boron tribromide in dichloromethane, or with aqueous hydrobromic acid and acetic acid, or with sodium ethanethiolate in dimethylformamide, at a temperature ranging from about  $0^\circ\text{C}$  to the about reflux temperature, as illustrated in Scheme 3. Room temperature is preferred when
- 10 boron tribromide is used, the reflux temperature is preferred when hydrobromic acid/acetic acid is used, and about  $100^\circ\text{C}$  to about  $120^\circ\text{C}$  is preferred when sodium ethanethiolate is used.


5

## SCHEME 8



5

## SCHEME 8 Continued





5           Compounds of the formula 25 can be converted into the corresponding compounds wherein the bromine substituent is replaced by an aromatic or heteroaromatic substituent using the procedure illustrated in Scheme 5 and discussed above. Compounds of the formula 26 can be converted into the corresponding compounds wherein  $R^2$  is  $-C(OH)R^5R^6$  rather than  $-COOR^7$  using the procedure described above and illustrated in Scheme 6. Compounds of  
10 the formula 28 can be derivatized to form the corresponding compounds wherein  $R^3$  is  $-CONH_2$  and  $-OC(=O)R^7$  using the procedures described above and illustrated in Schemes 4 and 7, respectively, for preparing compounds of the formula 12 (Scheme 4) and 16 (Scheme 7).

Scheme 9 illustrates a method for the preparation of compounds with the general  
15 formula I wherein X is nitrogen,  $R^3$  is methoxy, hydroxy,  $R^2$  is  $CONR^5R^6$  and  $R^1$  is as defined above. Referring to Scheme 9, compounds of the formula 31 can be obtained by the treatment of phenyl acetonitrile derivatives of the formula 29 with sodium hydride and a 2-bromopyridine or 2-halopyridine derivative of the formula 30 in dimethylformamide or in another suitable solvent such as tetrahydrofuran, at a temperature from about  $0^\circ\text{C}$  to about  
20 the reflux temperature, preferably at about  $60^\circ\text{C}$ .

Treatment of compounds of the formula 31 with sodium hydride in dimethylformamide or another suitable solvent such as tetrahydrofuran, at a temperature from about  $0^\circ\text{C}$  to about the reflux temperature, preferably at  $60^\circ\text{C}$ , followed by the treatment with an alkylating agent such as 1-bromo-3-chloropropane, at a temperature from about  $0^\circ\text{C}$  to about the reflux  
25 temperature, preferably at about  $60^\circ\text{C}$ , yields the corresponding compounds of formula 32.

Reduction of the cyano group of compounds of the formula 32 with a reducing agent such as diisobutyl aluminum hydride or another reducing metal hydride source such as lithium aluminum hydride, in a solvent such as methylene chloride, at a temperature from about  $-78^\circ\text{C}$  to about the reflux temperature, preferably at about  $-78^\circ\text{C}$ , and warming gradually to  
30 room temperature, affords the corresponding compounds of formula 33 after vigorous stirring in a saturated aqueous Rochelle's salt solution.

When  $R^1$  does not attach to the piperidine nitrogen at an aryl moiety or secondary alkyl carbon, compounds of the formula 33 can be converted into the corresponding compounds of formula 34 by reacting them with an aldehyde and sodium  
35 triacetoxyborohydride or another reducing agent (e.g., sodium borohydride or sodium cyanoborohydride), in dichloromethane, 1,2 dichloroethane or another suitable solvent such as methanol, ethanol or toluene, at a temperature ranging from about  $0^\circ\text{C}$  to about  $100^\circ\text{C}$ , preferably at about room temperature. When  $R^1$  attaches to the piperidine nitrogen via an aryl moiety or a primary or secondary alkyl carbon, compounds of the formula 34 can be produced

5 by alkylation or heteroarylation of compounds of the general formula 33 using conditions identical to those described for the preparation of compounds of the formula 7 in Scheme 2.


The compounds of formula 34 are then placed under a carbon monoxide atmosphere at a pressure ranging from about 14 to 100 psi, in a solution of dimethylsulfoxide and a lower alkanol such as methanol or ethanol, with a suitable trialkylamine base (e.g., triethylamine) and palladium acetate with 1,3-bis(diphenylphosphino)propane (DPPP) or another suitable palladium ligand. Other suitable palladium catalysts such as bis(triphenylphosphine) palladium dichloride may also be used. This reaction, which is typically conducted at temperatures ranging from about 20°C to about 100°C, yields the desired compound of formula 35.

15 Treatment of the ester of formula 35 with an aluminum amide of a primary or secondary amine, for example, diethyl amine, in a solvent such as dichloroethane or toluene, at a temperature ranging from about 20°C to about the reflux temperature, preferably at about the reflux temperature, yields the corresponding amide of formula 36.

Compounds of the formula 37 wherein R<sup>3</sup> is hydroxy can be prepared by deprotecting the corresponding alkyl ethers of formula 36 (wherein R<sup>3</sup> is OR<sup>10</sup> and R<sup>10</sup> is (C<sub>1</sub>-C<sub>6</sub>)alkyl) with boron tribromide in dichloromethane, or with aqueous hydrobromic acid and acetic acid, or with sodium ethanethiolate in dimethylformamide, at temperatures ranging from about 0°C to about the reflux temperature, as shown in Scheme 3. Room temperature is preferred when boron tribromide is used, the reflux temperature is preferred when hydrobromic acid/acetic acid is used, and about 100°C to about 120°C is preferred when sodium ethanmethiolate is used.


5

## SCHEME 9



5

## SCHEME 9 Continued




5           Compounds of the formula 34 can be converted into the corresponding compounds wherein the bromine substituent is replaced by an aromatic or heteroaromatic substituent using the procedure illustrated in Scheme 5 and discussed above. Compounds of the formula 35 can be converted into the corresponding compounds wherein  $R^2$  is  $-C(OH)R^5R^6$  rather than  $-COOR^7$  using the procedure described above and illustrated in Scheme 6. Compounds of  
10 the formula 37 can be derivatized to form the corresponding compounds wherein  $R^3$  is  $-CONH_2$  and  $-OC(=O)R^7$  using the procedures described above and illustrated in Schemes 4 and 7, respectively, for preparing compounds of the formula 12 (Scheme 4) and 16 (Scheme 7).

Scheme 10 illustrates a method for preparing compounds of the general formula I  
15 wherein  $R^3$  is  $NHSO_2R^7$ . Referring to Scheme 10, the phenol of formula 38 is converted into the triflate of formula 39 by the procedures illustrated in Schemes 1 and 4 and described above, after which the triflate is transformed into the ester of formula 40 by the procedure illustrated in Scheme 1 and described above. The ester of formula 40 can then be converted  
20 into the carboxylic acid of formula 41 by hydrolyzing it with lithium hydroxide in a water/THF solution at about room temperature. Treatment of the resulting carboxylic acid of formula 41 with diphenylphosphoryl azide and triethylamine in a tert-butanol solvent at about the reflux temperature yields the corresponding tert-butyl carbamate of formula 42. Acidic treatment of the carbamate of formula 42 with trifluoroacetic acid in methylene chloride yields the corresponding aniline of formula 43. The aniline of formula 43 can then be reacted with  
25 sulfonyl chloride, in the presence of a base such as pyridine or triethylamine, to yield the desired sulfonamide of formula I. This reaction is preferably carried out in a polar solvent such as methylene chloride, dichloroethane or THF, at a temperature from about 0°C to about the reflux temperature of the solvent.

5

## SCHEME 10



5           The preferred method of making compounds of the formula I wherein  $R^3$  is OH,  $NHSO_2R^7$ ,  $C(OH)R^7R^8$  or  $C(=O)NHR^7$  is to make the analogous compounds wherein  $R^3$  is O-( $C_1$ - $C_6$ )alkyl and then derivatize them using standard methods well known in art and illustrated in the foregoing schemes.

10           The starting materials used in the processes of Schemes 1-9 are either commercially available, known in the literature, or readily obtainable from commercially available or known compounds using methods that are well known in the art or described above.

          Unless indicated otherwise, the pressure of each of the above reactions is not critical. Generally, the reactions will be conducted at a pressure from about one to about three atmospheres, preferably at ambient pressure (about one atmosphere).

15           The preparation of other compounds of the formula I not specifically described in the foregoing experimental section can be accomplished using combinations of the reactions described above that will be apparent to those skilled in the art.

          The compounds of the formula I that are basic in nature are capable of forming a wide variety of different salts with various inorganic and organic acids. The acid that can be used to  
20           prepare the pharmaceutically acceptable acid addition salts of the base compounds of this invention are those which form non-toxic acid addition salts, i.e., salts containing pharmacologically acceptable anions, such as hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate or bisulfate, phosphate or acid phosphate, acetate, lactate, citrate or acid citrate, tartrate or bitartrate, succinate, maleate, fumarate, gluconate, saccharate, benzoate, methanesulfonate  
25           and pamoate [i.e., 1,1'-methylene-bis-(2-hydroxy-3-naphthoate)] salts. Although such salts must be pharmaceutically acceptable for administration to animals, it is often desirable in practice to initially isolate a compound of the formula I from the reaction mixture as a pharmaceutically unacceptable salt and then simply convert the latter back to the free base compound by treatment with an alkaline reagent, and subsequently convert the free base to a pharmaceutically  
30           acceptable acid addition salt. The acid addition salts of the base compounds of this invention are readily prepared by treating the base compound with a substantially equivalent amount of the chosen mineral or organic acid in an aqueous solvent medium or in a suitable organic solvent such as methanol or ethanol. Upon careful evaporation of the solvent, the desired solid salt is obtained.

35           Compounds of the formula that are acidic in nature are capable of forming base salts with various pharmacologically acceptable cations. These salts are all prepared by conventional techniques. The chemical bases that are used as reagents to prepare the pharmaceutically acceptable base salts of this invention are those which form non-toxic base salts with the acidic compounds of formula I. Such non-toxic base salts include those derived from such  
40           pharmacologically acceptable cations as sodium, potassium, calcium and magnesium, etc. These salts can easily be prepared by treating the corresponding acidic compounds with an aqueous solution containing the desired pharmacologically acceptable cations, and then

5 evaporating the resulting solution to dryness, preferably under reduced pressure. Alternatively, they may also be prepared by mixing lower alkanolic solutions of the acidic compounds and the desired alkali metal alkoxide together, and then evaporating the resulting solution to dryness in the same manner as before. In either case, stoichiometric quantities of reagents are preferably employed in order to ensure completeness of reaction and maximum yields of the desired final  
10 product.

The compounds of the formula I and the pharmaceutically acceptable salts thereof (hereinafter, also referred to, collectively, as "the active compounds of the invention") are useful for the treatment of neurodegenerative, psychotropic and drug or alcohol induced deficits and are potent opioid receptor ligands. The active compounds of the invention may therefore be used in  
15 the treatment of disorders and conditions, such as those enumerated above, that can be treated by modulating binding to an opioid receptor.

The ability of the compounds of formula I to bind to the various opioid receptors and their functional activity at such receptors can be determined as described below. Binding to the delta opioid receptor can be determined using procedures well known in the art, such as those  
20 referred to by Lei Fang *et al.*, *J. Pharm. Exp. Ther.*, 268, 1994, 836 - 846 and Contreras *et al.*, *Brain Research*, 604, 1993, 160 - 164.

In the description of binding and functional assays that follows, the following abbreviations and terminology are used.

DAMGO is [D-Ala<sup>2</sup>,N-MePhe<sup>4</sup>,Gly<sup>5</sup>-o]enkephalin).

25 U69593 is ((5a, 7a, 8b)-(+)-N-methyl-N-(7-[1-pyrrolidinyl]-1-oxasipropyl[4,5]dec-8-yl)-benzeneacetamide).

SNC-80 is (+)-4-[( $\alpha$ R)- $\alpha$ [(2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl]-3-methoxybenzyl]-N,N-diethylbenzamide.

nor BNI is nor-binaltorphimine.

30 CTOP is 1,2-Dithia-5,8,11,14,17-pentaazacycloicosane, cyclic peptide derivative DPDPE is [D-en<sup>2</sup>,D-Pen<sup>5</sup>]enkephalin).

[<sup>3</sup>H]-DAMGO, [<sup>3</sup>H]-U69593, norBNI, and CTOP are all commercially available from DuPont, Amersham International, RBI and DuPont, Amersham International, RBI and DuPont respectively.

35 [<sup>3</sup>H]-SNC80 was prepared by Amersham International.

Opioid ( $\mu$  and  $\kappa$ ) receptor binding assays can be performed in guinea-pig brain membrane preparations. Binding assays can be carried out at 25°C for 60 minutes in 50 mM Tris (pH 7.4) buffer. [<sup>3</sup>H]-DAMGO (2 nM) and [<sup>3</sup>H]-U-69,593 (2 nM) can be used to label  $\mu$  and  $\kappa$  receptor binding sites, respectively. The protein concentration can be  
40 approximately 200  $\mu$ g/well. Non-specific binding can be defined with 10  $\mu$ M naloxone.



5 Delta receptor binding assays can be performed in a stable line of CHO cells expressing the human delta receptor. The binding assay can be carried out at 25°C for 120 minutes in 50 mM Tris (pH 7.4) buffer. [<sup>3</sup>H]-SNC-80 can be used to label delta receptor binding sites. The protein concentration can be approximately 12.5 µg/well. Non-specific binding can be defined with 10 µM naltrexone.

10 The binding reaction can be terminated by rapid filtration through glass fibre filters, and the samples can be washed with ice-cold 50 mM Tris buffer (pH 7.4).

Agonist activity at the delta, mu and kappa opioid receptors can be determined as follows.

15 Opioid (delta, mu and kappa) activity is studied, as described below, in two isolated tissues, the mouse deferens (MVD)(δ) and the guinea-pig myentric plexus with attached longitudinal muscle (GPMP) (µ and κ).

MVD (DC1 strain, Charles River, 25-35 g) are suspended in 15 ml organ baths containing Mg<sup>++</sup> free Krebs' buffer of the following composition (mM): NaCl, 119; KCl, 4.7; NaHCO<sub>3</sub>, 25; KH<sub>2</sub>PO<sub>4</sub>, 1.2; CaCl<sub>2</sub>, 2.5 and glucose, 11. The buffer is gassed with 95%O<sub>2</sub> and 20 5% CO<sub>2</sub>. The tissues are suspended between platinum electrodes, attached to an isometric transducer with 500 mg tension and stimulated with 0.03 Hz pulses of 1-msec pulse-width at supramaximal voltage. IC<sub>50</sub> values are determined by the regression analysis of concentration-response curves for inhibition of electrically-induced contractions in the presence of 300 nM of the mu-selective antagonist CTOP. This test is a measure of δ 25 agonism.

Guinea-pig (Porcellus strain, male, 450-500 g, Dunkin Hartley) myentric plexus with attached longitudinal muscle segments are suspended with 1 g of tension in Krebs' buffer and stimulated with 0.1 Hz pulses of 1-msec pulse-width at supramaximal voltage. Mu functional activity is determined in the presence of 10 nM nor-BNI with 1 µM of the mu selective agonist, 30 DAMGO, added to the bath at the end of the experiment to define a maximal response. This test is a measure of mu agonism.

Kappa functional activity is determined in the presence of and 1 µM CTOP with 1 µM of the kappa selective agonist U-69,593 added at the end of the experiment to define a maximal response. All inhibitions of twitch height for test compounds are expressed as a 35 percentage of the inhibition obtained with the standard agonist and the corresponding IC<sub>50</sub> values determined.

The following procedure can be used to determine the activity of the therapeutic agents of this invention as agonists and as antagonists of delta opioid receptors.

40 Cell Culture: Chinese hamster ovary cells expressing the human delta opioid receptor are passaged twice weekly in Hamis F-12 media with L-glutamine containing 10% fetal bovine serum and 450 µg/mL hygromycin. Cells are prepared for assays 3 days prior to the

5 experiment. 15 mL of 0.05% trypsin/EDTA is added to a confluent triple flask, swirled and decanted to rinse. 15 mL of 0.05% trypsin/EDTA is again added, and the flask is placed into a 37C incubator for 2 minutes. Cells are removed from the flask by banking, and supernatant poured off into a 50 mL tube. 30 mL of media is then added to the flask to stop the action of the trypsin, and then decanted into the 50 mL tube. Tube is then centrifuged for 5 minutes at  
10 1000 rpm, media decanted, and the pellet resuspended into 10 mL of media. Viability of the cells is assessed using trypan blue, the cells counted and plated out into 96 well poly-D-lysine coated plates at a density of 7,500 cells/well.

Antagonist Test Plate: Cells plated 3 days prior to assay are rinsed twice with PBS. The plates are placed into a 37C water bath. 50 µL of assay buffer (PBS, dextrose 1 mg/mL,  
15 5mM MgCl<sub>2</sub>, 30 mM HEPES, 66.7 µg/mL of IBMX) is then added to designated wells. Fifty microliters of appropriate drug is then added to designated wells, and timed for 1 minute. Fifty microliters of 10 µM forskolin + 0.4nM DPDPE (final assay concentration is 5 µM forskolin, 0.2nM DPDPE) is then added to appropriate wells, and timed for 15 minutes. The reaction is stopped by the addition of 10 µL of 6N perchloric acid to all wells. To neutralize, 13 µL of 5N  
20 KOH is added to all wells, and to stabilize 12 µL of 2M Tris, pH 7.4 is added to all wells. Mix by shaking on an orbital shaker for 10 minutes, and centrifuge at setting 7 for 10 minutes. Aliquot into 3H plate.

Agonist Test Plate: Cells plated 3 days prior to assay are rinsed twice with PBS. The plates are placed into a 37°C water bath. Fifty microliters of assay buffer (PBS, dextrose 1  
25 mg/mL, 5mM MgCl<sub>2</sub>, 30mM HEPES, 66.7 µg/mL of IBMX) is then added to designated wells. Fifty microliters of appropriate drug + 10 µM forskolin (final assay concentration is 5µM forskolin) is then added to all wells, and timed for 15 minutes. The reaction is then stopped by the addition of 10 µL of 6N perchloric acid to all wells. To neutralize, 13 µ of 5N KOH is added to all wells, and to stabilize 12 µL of 2M Tris, pH 7.4 is added to all wells. Mix by shaking on an  
30 orbital shaker for 10 minutes, and centrifuge at setting 7 for 10 minutes. Aliquot into 3H plate.

Both test plates are placed into an Amersham 3H cAMP binding kit overnight, and harvested onto GF/B filters previously soaked in 0.5% PEI with a Skatron using 50 mM Tris HCl pH 7.4 at 4°C. Filtermats can be air-dried overnight then place in bags with 20 ml Betaplate scintillation cocktail and counted on a Betaplate counter for 60 sec per sample.  
35 Data can be analyzed using Excel.

The compositions of the present invention may be formulated in a conventional manner using one or more pharmaceutically acceptable carriers. Thus, the active compounds of the invention may be formulated for oral, buccal, transdermal (e.g., patch), intranasal, parenteral (e.g., intravenous, intramuscular or subcutaneous) or rectal administration or in a form suitable  
40 for administration by inhalation or insufflation.

5 For oral administration, the pharmaceutical compositions may take the form of, for example, tablets or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g., pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (e.g., lactose, microcrystalline cellulose or calcium phosphate); lubricants (e.g., magnesium stearate, talc or silica); disintegrants (e.g., potato starch or sodium starch glycollate); or wetting agents (e.g., sodium lauryl sulphate). The tablets may be coated by methods well known in the art. Liquid preparations for oral administration may take the form of, for example, solutions, syrups or suspensions, or they may be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations may be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (e.g., sorbitol syrup, methyl cellulose or hydrogenated edible fats); emulsifying agents (e.g., lecithin or acacia); non-aqueous vehicles (e.g., almond oil, oily esters or ethyl alcohol); and preservatives (e.g., methyl or propyl p-hydroxybenzoates or sorbic acid).

For buccal administration the composition may take the form of tablets or lozenges formulated in conventional manner.

20 The active compounds of the invention may be formulated for parenteral administration by injection, including using conventional catheterization techniques or infusion. Formulations for injection may be presented in unit dosage form, e.g., in ampules or in multi-dose containers, with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulating agents such as suspending, stabilizing and/or dispersing agents. Alternatively, the active ingredient may be in powder form for reconstitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.

The active compounds of the invention may also be formulated in rectal compositions such as suppositories or retention enemas, e.g., containing conventional suppository bases such as cocoa butter or other glycerides.

30 For intranasal administration or administration by inhalation, the active compounds of the invention are conveniently delivered in the form of a solution or suspension from a pump spray container that is squeezed or pumped by the patient or as an aerosol spray presentation from a pressurized container or a nebulizer, with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol, the dosage unit may be determined by providing a valve to deliver a metered amount. The pressurized container or nebulizer may contain a solution or suspension of the active compound. Capsules and cartridges (made, for example, from gelatin) for use in an inhaler or insufflator may be formulated containing a powder mix of a compound of the invention and a suitable powder base such as lactose or starch.

40 In general, a therapeutically effective daily oral or intravenous dose of the compounds of formula (I) and their salts is likely to range from 0.001 to 50 mg/kg body weight of the subject to be treated, preferably 0.1 to 20 mg/kg. The compounds of the formula (I) and their

- 5 salts may also be administered by intravenous infusion, at a dose which is likely to range from 0.001-10 mg/kg/hr.

Tables or capsules of the compounds may be administered singly or two or more at a time as appropriate. It is also possible to administer the compounds in sustained release formulations.

- 10 The physician will determine the actual dosage which will be most suitable for an individual patient and it will vary with the age, weight and response of the particular patient. The above dosages are exemplary of the average case. There can, of course, be individual instances where higher or lower dosage ranges are merited, and such are within the scope of this invention.

- 15 Alternatively, the compounds of the formula (I) can be administered by inhalation or in the form of a suppository or pessary, or they may be applied topically in the form of a lotion, solution, cream, ointment or dusting powder. An alternative means of transdermal administration is by use of a skin patch. For example, they can be incorporated into a cream consisting of an aqueous emulsion of polyethylene glycols or liquid paraffin. They can also be  
20 incorporated, at a concentration of between 1 and 10% by weight, into an ointment consisting of a white wax or white soft paraffin base together with such stabilisers and preservatives as may be required.

- The following Examples illustrate the preparation of the compounds of the present invention. Commercial reagents were utilized without further purification. All NMR data were  
25 recorded at 250, 300 or 400 MHz in deuteriochloroform unless otherwise specified and are reported in parts per million ( $\delta$ ) and are referenced to the deuterium lock signal from the sample solvent. All non-aqueous reactions were carried out in dry glassware with dry solvents under an inert atmosphere for convenience and to maximize yields. All reactions were stirred with a magnetic stirring bar unless otherwise stated. Unless otherwise stated, all mass spectra were  
30 obtained using chemical impact conditions. Ambient or room temperature refers to 20-25°C.

5

**EXAMPLE 1****N,N-DIETHYL-4-[3-(3-METHOXY-PHENYL)-PIPERIDIN-3-YL]-BENZAMIDE****A. 1-Benzyl-3-(3-methoxy-phenyl)-piperidin-3-ol**

To a suspension of magnesium (7.8 g, 325 mmol) in THF (120 mL) at room temperature under a nitrogen atmosphere was added a solution of 3-bromoanisole (37.5 mL, 296 mmol) in THF (60 mL) over 10 min. The resulting mixture was stirred at 50°C for 4 hours and was cooled to room temperature. To the mixture was added a solution of N-benzyl-3-piperidinone (30.0 g, 159 mmol) in THF (50 mL). The reaction was stirred at room for 10 hours. The mixture was poured slowly over ice-water (100 mL) and the aqueous layer was washed with EtOAc (3 x 50 mL). The combined organic extracts were dried (MgSO<sub>4</sub>) and concentrated. The crude residue was purified by flash chromatography with hexanes/EtOAc (3:1) to afford 38.4 g of 1-benzyl-3-(3-methoxy-phenyl)-piperidin-3-ol <sup>1</sup>HNMR (400 MHz, CDCl<sub>3</sub>) δ 7.31-7.20 (comp, 6H), 7.09 (s, 1H), 7.01 (d, 1H), 6.79 (d, 1H), 4.01-3.96 (br, 1H), 3.79 (s, 3H), 3.58 (s, 2H), 2.91 (d, 1H), 2.74 (d, 1H), 2.32 (d, 1H), 2.09-1.82 (comp, 2H), 1.81-1.61 (comp, 3H); MS (M+1) 298.2.

**B. 4-[1-Benzyl-3-(3-methoxy-phenyl)-piperidin-3-yl]-phenol**

To a solution of 1-benzyl-3-(3-methoxy-phenyl)-piperidin-3-ol (17.6 g, 73.1 mmol) in (CH<sub>2</sub>)<sub>2</sub>Cl<sub>2</sub> (200 mL) was added phenol (16.7 g, 178 mmol) followed by portionwise addition (highly exothermic) of AlCl<sub>3</sub> (23.3g, 178 mmol). The reaction mixture was heated to reflux for 2 hours. The mixture was cooled to room temperature and was slowly poured into a mixture of crushed ice (50 mL) and 30 % aq. NH<sub>4</sub>OH (120 mL). The mixture was stirred vigorously for 20 minutes and was then filtered through celite. The celite cake was washed with CH<sub>2</sub>Cl<sub>2</sub> (200 mL). The organic layer was separated and the aqueous layer was washed with CH<sub>2</sub>Cl<sub>2</sub> (3 x 100 mL). The combined organic layers were dried (MgSO<sub>4</sub>) and concentrated. The crude residue was purified by flash chromatography with hexanes/EtOAc (1:1) to afford 16.3 g of 4-[1-benzyl-3-(3-methoxy-phenyl)-piperidin-3-yl]-phenol <sup>1</sup>HNMR (400 MHz, CDCl<sub>3</sub>) δ 7.39-7.21 (comp, 5H), 7.19-7.05 (comp, 3H), 6.84 (s, 1H), 6.79 (d, 1H), 6.67-6.61 (comp, 3H), 3.73 (s, 3H), 3.50 (s, 2H), 2.86-2.79 (comp, 2H), 2.45-2.38 (comp, 2H), 2.21-2.19 (comp, 2H), 1.60-1.51 (comp, 2H); MS (M+1) 374.2.

**C. Trifluoro-methanesulfonic acid 4-[1-benzyl-3-(3-methoxy-phenyl)-piperidin-3-yl]-phenyl ester**

To a slurry of 4-[1-benzyl-3-(3-methoxy-phenyl)-piperidin-3-yl]-phenol (10.4 g, 27.8mmol) in CH<sub>2</sub>Cl<sub>2</sub> (60 mL) at 0°C was added pyridine (3.37 mL, 41.7 mmol) followed by dropwise addition of triflic anhydride (5.62 mL, 27.8 mmol) over 5 minutes. The reaction mixture was stirred at 0°C for 1 hour and at room temperature for 2 hours. The solution was then cooled to 0°C and 40 mL of cold saturated aqueous NaHCO<sub>3</sub> were added. The organic

5 layer was separated and the aqueous layer was washed with  $\text{CH}_2\text{Cl}_2$  (3 x 50 mL). The combined organic layers were dried ( $\text{MgSO}_4$ ) and concentrated. The crude residue was purified by flash chromatography with hexanes/EtOAc (4:1) to afford 9.81 g of Trifluoro-methanesulfonic acid 4-[1-benzyl-3-(3-methoxy-phenyl)-piperidin-3-yl]-phenyl ester.  $^1\text{H}$ NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.39-7.22 (comp, 7H), 7.15 (t, 1H), 7.09 (d, 2H), 6.76-6.67 (comp, 3H),  
10 3.72 (s, 3H), 3.52-3.49 (comp, 2H), 3.08-2.91 (m, 1H), 2.2.72-2.60 (m, 1H), 2.59-2.49 (m, 1H), 2.41-2.29 (m, 1H), 2.23-2.19 (comp, 2H), 1.61-1.41 (comp, 2H); MS (M+1) 506.1.

**D. 4-[1-Benzyl-3-(3-methoxy-phenyl)-piperidin-3-yl]-benzoic acid methyl ester**

To a solution of trifluoro-methanesulfonic acid 4-[1-benzyl-3-(3-methoxy-phenyl)-piperidin-3-yl]-phenyl ester (12.9 g, 25.4 mmol) in a Parr pressure bottle in MeOH (39 mL)  
15 were added DMSO (18 mL) and triethylamine (21 mL, 151 mmol). To the reaction mixture were added palladium acetate (3.99 g, 17.8 mmol) and 1,3-bis (diphenylphosphino) propane (5.25 g, 12.3 mmol). The mixture was shaken under 40 psi of CO at 70°C for 4 hours. The reaction mixture was cooled to room temperature and was diluted with diethyl ether (600 mL).  
20 The ether layer was washed with water (5 x 60 mL), dried ( $\text{MgSO}_4$ ) and concentrated. The crude residue was purified by flash chromatography with hexanes/EtOAc (3:1) to afford 9.82 g of 4-[1-benzyl-3-(3-methoxy-phenyl)-piperidin-3-yl]-benzoic acid methyl ester.  $^1\text{H}$ NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.87 (d, 2H), 7.41-7.20 (comp, 7H), 7.12 (t, 1H), 6.77 (s, 1H), 6.73 (d, 1H), 6.66 (d, 1H), 3.86 (s, 3H), 3.71 (s, 3H), 3.51 (s, 2H), 3.05 (br, 1H), 2.68 (br, 1H), 2.55 (br, 1H),  
25 2.41-2.24 (comp, 2H), 2.22-2.18 (m, 1H) 1.61-1.42 (comp, 2H); MS (M+1) 416.3.

**E. 4-[1-Benzyl-3-(3-methoxy-phenyl)-piperidin-3-yl]-N,N-diethyl-benzamide**

To a solution of diethyl amine (8.21 mL, 79.6 mmol) in  $\text{CH}_2\text{ClCH}_2\text{Cl}$  (20 mL) at room temperature was added a trimethylaluminum (39.8 mL, 79.6 mmol, 2M in hexanes) dropwise. The reaction mixture was stirred at room temperature for 1 hour. A solution of 4-[1-benzyl-3-(3-methoxy-phenyl)-piperidin-3-yl]-benzoic acid methyl ester (6.0 g, 14.5 mmol) in  $(\text{CH}_2)_2\text{Cl}_2$  (6 mL) was added and the reaction mixture was heated to reflux for 14 hours (h). The solution was then cooled 0°C and sat. aqueous sodium bicarbonate ( $\text{NaHCO}_3$ ) (15 mL) was added dropwise. The mixture was filtered through celite. The celite cake was washed with  $\text{CH}_2\text{Cl}_2$  (40 mL). The organic layer was separated and the aqueous layer was washed with  $\text{CH}_2\text{Cl}_2$  (3  
35 x 30 mL). The combined organic layers were dried over magnesium sulfate ( $\text{MgSO}_4$ ) and concentrated. The crude residue was purified by flash chromatography with ethyl acetate (EtOAc) to afford 6.57 g of 4-[1-benzyl-3-(3-methoxy-phenyl)-piperidin-3-yl]-N,N-diethyl-benzamide.  $^1\text{H}$ NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.41-7.20 (comp, 9H), 7.14 (t, 1H), 6.82 (s, 1H), 6.75 (d, 1H), 6.66 (d, 1H), 3.73 (s, 3H), 3.68-3.51 (comp, 2H), 3.50 (s, 2H), 3.32-3.21 (comp, 2H),  
40 2.98-2.89 (m, 1H), 2.82-2.74 (m, 1H), 2.65-2.59 (m, 1H), 2.56-2.32 (comp, 2H), 2.29-2.19

5 (comp, 3H), 1.57-1.49 (comp, 1H), 1.23-1.10 (comp, 3H), 1.09-1.04 (comp, 2H); MS (M+1) 457.3.

F. **N,N-Diethyl-4-[3-(3-methoxy-phenyl)-piperidin-3-yl]-benzamide**

To a solution of 4-[1-benzyl-3-(3-methoxy-phenyl)-piperidin-3-yl]-N,N-diethyl-benzamide in acetic acid (8 mL) in a Parr pressure bottle was added palladium hydroxide  
10 (Pd(OH)<sub>2</sub>) (10% on carbon, 0.4 g). The reaction mixture was shaken under 50 psi of H<sub>2</sub> for 20 hours. The reaction mixture was then filtered through celite. The celite cake was washed with EtOAc. Diethyl-4-[3-(3-methoxy-phenyl)-piperidin-3-yl]-benzamide as the acetate salt. <sup>1</sup>HNMR (400 MHz, CDCl<sub>3</sub>) δ 7.39-7.17 (comp, 5H), 6.84-6.61 (comp, 3H), 3.74 (s, 3H), 3.73-3.60 (comp, 2H), 3.57-3.41 (comp, 2H), 3.38-3.14 (comp, 2H), 3.11-2.89 (comp, 2H), 2.48-2.26  
15 (comp, 2H), 1.81-1.66 (comp, 2H), 1.21-1.70 (comp, 3H), 1.06-0.99 (comp, 3H); MS (M+1) 367.4.

The following compounds were made using the procedure set forth above in Example 1, starting with a compound analogous to the title compound of Example 1A wherein R<sup>3</sup> is fluoro or methoxy, and adding the appropriate amine reactant in the procedure of Example 1E.

20 **4-[1-Benzyl-3-(3-methoxy-phenyl)-piperidin-3-yl]-N-ethyl-N-methyl-benzamide**

<sup>1</sup>HNMR (400 MHz, CDCl<sub>3</sub>) δ 7.31 (d, 4H), 6.82 (s, 1H), 6.76 (d, 2H), 6.67 (dd, 1H), 3.71 (s, 3H), 3.53 (br, 1H), 3.50 (s, 2H), 3.27 (br, 1H), 2.25-2.21 (comp, 2H); MS (M+1) 443.3.

**4-[1-Benzyl-3-(3-fluoro-5-methoxy-phenyl)-piperidin-3-yl]-N,N-diethyl-benzamide**

<sup>1</sup>HNMR (400 MHz, CDCl<sub>3</sub>) δ 7.33-7.29 (comp, 4H), 7.25-7.21 (comp, 5H), 6.59 (s,  
25 1H), 6.54 (d, 1H), 6.39 (dt, 1H), 3.69 (s, 3H), 3.54-3.45 (comp, 4H), 3.24 (br, 2H), 2.80 (br, 2H); MS (M+1) 475.3.

**4-[1-Benzyl-3-(3-methoxy-phenyl)-piperidin-3-yl]-N-(2,2,2-trifluoro-ethyl)-benzamide**

<sup>1</sup>HNMR (400 MHz, CDCl<sub>3</sub>) δ 7.64 (d, 2H), 6.76-6.66 (comp, 3H), 6.30 (br, 1H), 4.11-  
30 4.07 (comp, 2H), 3.51 (s, 2H), 2.24-2.19 (comp, 1H); MS (M+1) 483.3.

**EXAMPLE 2**

**GENERAL PROCEDURE FOR THE REDUCTIVE ALKYLATION OF N,N-DIETHYL-**

**4-[3-(3-METHOXY-PHENYL)-PIPERIDIN-3-YL]-BENZAMIDE**

To a solution of N,N-diethyl-4-[3-(3-methoxy-phenyl)-piperidin-3-yl]-benzamide (1  
35 equivalent) in methylene chloride (CH<sub>2</sub>Cl<sub>2</sub>) (0.4M) was added the aldehyde (1.2 equivalents) followed by addition of acetic acid (1.2 equivalents) and NaBH(OAc)<sub>3</sub> (1.5 equivalents). The reaction mixture was stirred at room temperature for 16 hours. The mixture was then partitioned between equal volumes of CH<sub>2</sub>Cl<sub>2</sub> and sat. aqueous sodium bicarbonate (NaHCO<sub>3</sub>). The organic layer was separated and the aqueous layer was washed with CH<sub>2</sub>Cl<sub>2</sub>  
40 (3X). The combined organic layers were dried (MgSO<sub>4</sub>) and concentrated. Purification by flash chromatography afforded the desired tertiary amines in yields ranging from 60-95%.

5 The following compounds were made using a procedure similar to that of Example 2, starting with a diarylsubstituted pyridine wherein R<sup>3</sup> is fluoro or methoxy and R<sup>2</sup> is the appropriate amide group.

**4-[1-Cyclopropylmethyl-3-(3-methoxy-phenyl)-piperidin-3-yl]-N,N-diethyl-benzamide**

10 <sup>1</sup>HNMR (400 MHz, CDCl<sub>3</sub>) δ 7.34 (d, 2H), 7.24 (dd, 2H), 7.13 (t, 1H), 6.91 (s, 1H), 6.84 (d, 1H), 6.66 (dd, 1H), 3.71 (s, 3H), 3.48 (br, 2H), 3.25 (br, 2H), 3.05-2.80 (comp, 2H), 2.48 (br, 2H), 2.29-2.20 (comp, 4H), 1.60-1.50 (comp, 2H), 1.23 (br, 3H), 1.08 (br, 3H), 1.00-0.92 (comp, 1H), 0.52 (d, 2H), 0.12 (d, 2H); MS (M+1) 421.3.

**4-[1-Cyclopropylmethyl-3-(3-methoxy-phenyl)-piperidin-3-yl]-N,N-diisopropyl-benzamide**

15 <sup>1</sup>HNMR (400 MHz, CDCl<sub>3</sub>) δ 7.31 (d, 2H), 6.92 (s, 1H), 6.85 (d, 1H), 6.67 (d, 1H), 2.48 (br, 2H), 2.25 (d, 4H), 1.02-0.93 (comp, 1H) 0.90-0.80 (comp, 2H), 0.53 (d, 2H), 0.12 (d, 2H); MS (M+1) 449.3.

**4-[1-Cyclopropylmethyl-3-(3-methoxy-phenyl)-piperidin-3-yl]-phenyl-(3,4-dihydro-1H-isoquinolin-2-yl)-methanone**

20 <sup>1</sup>HNMR (400 MHz, CDCl<sub>3</sub>) δ 7.37 (q, 4H), 6.91 (s, 1H), 6.84 (d, 1H), 6.69 (d, 1H), 3.74 (s, 3H), 2.94-2.80 (comp, 4H), 2.47 (br, 1H), 2.28 (br, 4H), 0.55 (d, 2H), 0.15 (br, 2H); MS (M+1) 421.3.

**4-[1-Cyclopropylmethyl-3-(3-methoxy-phenyl)-piperidin-3-yl]-phenyl-piperidin-1-yl-methanone**

25 <sup>1</sup>HNMR (400 MHz, CDCl<sub>3</sub>) δ 7.35 (d, 2H), 7.15 (t, 1H), 6.92 (s, 1H), 6.84 (d, 1H), 6.67 (d, 1H), 3.74 (s, 3H), 3.66-3.60 (comp, 2H), 3.40-3.34 (comp, 2H), 2.25 (d, 4H), 0.53 (d, 2H), 0.12 (d, 2H); MS (M+1) 433.3.

**4-[1-Cyclopropylmethyl-3-(3-methoxy-phenyl)-piperidin-3-yl]-phenyl-morpholin-4-yl-methanone**

30 <sup>1</sup>HNMR (400 MHz, CDCl<sub>3</sub>) δ 7.39 (d, 2H), 7.27 (d, 2H), 6.90 (s, 1H), 6.83 (d, 1H), 6.68 (d, 1H), 2.25 (d, 4H), 0.53 (d, 2H), 0.12 (d, 2H); MS (M+1) 435.3.

**N,N-Diethyl-4-[1-ethyl-3-(3-methoxy-phenyl)-piperidin-3-yl]-benzamide**

35 <sup>1</sup>HNMR (400 MHz, CDCl<sub>3</sub>) δ 7.32 (d, 2H), 6.89 (s, 1H), 6.82 (d, 1H), 6.67 (dd, 1H), 3.74 (s, 3H), 3.50 (br, 2H), 2.42 (q, 4H) 2.25-2.22 (comp, 2H); MS (M+1) 395.2.

**EXAMPLE 3**

**ALKYLATION OF N,N-DIETHYL-4-[3-(3-METHOXY-PHENYL)-PIPERIDIN-3-YL]-BENZAMIDE**

To a solution of N,N-diethyl-4-[3-(3-methoxy-phenyl)-piperidin-3-yl]-benzamide(1  
40 equivalent) in DMF (0.5M) was added potassium carbonate (K<sub>2</sub>CO<sub>3</sub>) (3-10 equivalents) and the alkyl or heteroaryl halide (1-5 equivalents). The reaction mixture was stirred at 60-120°C for



- 5 3-16 hours. The mixture was then cooled to room temperature and filtered. The filtrate was diluted with diethyl ether and the ether layer was washed with brine. The organic phase was dried (MgSO<sub>4</sub>) and concentrated. Purification by flash chromatography afforded the desired amines in yields ranging from 30-85%.

The following compounds were made using a procedure analogous to that of Example  
10 3, starting with the appropriate amide group.

**N,N-Diethyl-4-[3-(3-methoxy-phenyl)-1-pyrimidin-2-yl-piperidin-3-yl]-benzamide**

- <sup>1</sup>HNMR (400 MHz, CDCl<sub>3</sub>) δ 8.35 (d, 2H), 7.33 (d, 2H), 7.23 (d, 2H), 7.14 (t, 1H), 6.91 (s, 1H), 6.86 (d, 1H), 6.68 (dd, 1H), 6.49 (t, 1H), 4.29 (q, 2H), 3.87-3.80 (comp, 1H), 3.76-3.69 (comp, 1H), 3.67 (s, 3H), 3.49 (br, 2H), 3.21 (br, 2H), 2.51-2.47 (comp, 2H), 1.62 (br, 2H),  
15 1.18(br, 3H), 1.06 (br, 3H); MS (M+1) 445.4.

**N,N-Diethyl-4-[3-(3-methoxy-phenyl)-3,4,5,6-tetrahydro-2H-[1,2]bipyridinyl-3-yl]-benzamide**

<sup>1</sup>HNMR (400 MHz, CDCl<sub>3</sub>) δ 8.24-8.22 (comp, 1H), 7.33 (d, 2H), 6.92 (s, 1H), 6.86 (d, 1H), 6.69 (dd, 2H), 4.10 (q, 2H), 3.23 (br, 2H), 2.45 (br, 2H); MS (M+1) 444.2.

- 20 **4-[1-Benzooxazol-2-yl-3-(3-methoxy-phenyl)-piperidin-3-yl]-N,N-diethyl-benzamide**

<sup>1</sup>HNMR (400 MHz, CDCl<sub>3</sub>) δ 7.41 (d, 1H), 7.04 (t, 1H), 6.90-6.86 (comp, 2H), 6.71 (dd, 1H), 4.18 (br, 2H), 3.49 (br, 2H), 2.51-2.45 (comp, 2H), 1.69 (br, 2H); MS (M+1) 484.4.

- 25 **N,N-Diethyl-4-[1-(5-fluoro-pyrimidin-2-yl)-3-(3-methoxy-phenyl)-piperidin-3-yl]-benzamide**

<sup>1</sup>HNMR (400 MHz, CDCl<sub>3</sub>) δ 8.23 (s, 2H), 7.15 (t, 1H), 7.90-7.84 (comp, 2H), 6.69 (dd, 1H), 4.23 (q, 2H) 3.49 (br, 2H), 2.48-2.45 (comp, 2H), 1.62-1.57 (comp, 2H); MS (M+1) 463.3.

**4-[1-Allyl-3-(3-methoxy-phenyl)-piperidin-3-yl]-N,N-diethyl-benzamide**

- <sup>1</sup>HNMR (400 MHz, CDCl<sub>3</sub>) δ 7.29 (d, 2H), 7.23 (d, 2H), 7.12 (t, 1H), 6.86 (s, 1H), 5.99-  
30 5.89 (comp, 1H), 5.19-5.13 (comp, 2H), 3.70 (s, 3H), 3.48 (br, 2H), 2.98 (d, 2H), 2.44 (br, 2H),  
2.24-2.19 (comp, 2H); MS (M+1) 407.3.

**EXAMPLE 4**

**DEPROTECTION OF METHYL ARYL ETHERS**

- To a solution of methyl ether (1 equivalent) in CH<sub>2</sub>Cl<sub>2</sub> (0.4M) at -78°C was added a  
35 solution of boron tribromide (1-5 equivalents) in CH<sub>2</sub>Cl<sub>2</sub> (1.0M) dropwise. The reaction mixture was stirred at -78°C for 1 hour was warmed to room temperature and stirred for an additional 4-6 hour. The mixture was quenched with slow addition of water and was brought to pH 8 with a saturated water/ammonium hydroxide (NH<sub>4</sub>OH) solution. The aqueous layer was washed with CH<sub>2</sub>Cl<sub>2</sub>. The organic phase was dried (MgSO<sub>4</sub>) and concentrated. Purification by flash  
40 chromatography afforded the desired phenols in yields ranging from 60-95%.

5 Alternatively, the methyl ethers were deprotected with sodium hydride and ethane thiol  
in dimethylformamide (DMF) as follows: To a suspension of sodium hydride (NaH) (10  
equivalents) in DMF (0.2M) at room temperature was added ethane thiol (10 equivalents)  
dropwise. The mixture was stirred for 5 minutes. To the reaction mixture was added a  
10 solution of the methyl ether (1 equivalent) in DMF (0.2M). The mixture was heated to 120°C  
for 10-16 hours. The reaction was cooled to room temperature and was quenched with water.  
The mixture was diluted with diethyl ether and the organic layer was washed with brine. The  
organic phase was dried (MgSO<sub>4</sub>) and concentrated. Purification by flash chromatography  
afforded the desired phenols in yields ranging from 60-95%.

The following compounds were made using a procedure similar to that of Example 4.

15 **4-[1-Benzyl-3-(3-hydroxy-phenyl)-piperidin-3-yl]-N,N-diethyl-benzamide**

<sup>1</sup>HNMR (400 MHz, CDCl<sub>3</sub>) δ 7.31-7.29 (comp, 4H), 7.28-7.19 (comp, 5H), 7.03 (t, 1H),  
6.72 (d, 1H), 6.62 (s, 1H), 6.57 (dt 1H), 3.58-3.42 (comp, 4H), 3.47 (s, 2H), 3.25 (br, 2H), 2.88  
(br, 1H), 2.72 (br, 1H), 2.49 (br, 1H), 2.38 (br, 1H), 2.25-1.95 (comp, 2H), 1.59-1.42 (comp,  
2H), 1.20 (br, 3H), 1.09 (br, 3H); MS (M+1) 443.3.

20 **N,N-Diethyl-4-[3-(3-hydroxy-phenyl)-1-(3-phenyl-propyl)-piperidin-3-yl]-  
benzamide**

<sup>1</sup>HNMR (400 MHz, CDCl<sub>3</sub>) δ 7.31-7.14 (comp, 9H), 7.79 (d, 1H), 6.70 (s, 1H), 6.57  
(dd, 1H), 3.49 (br, 2H), 2.93 (br, 1H), 2.66-2.60 (comp, 2H), 2.23-2.17 (comp, 2H), 1.20 (br,  
3H); MS (M+1) 471.2.

25 **4-[1-Cyclopropylmethyl-3-(3-hydroxy-phenyl)-piperidin-3-yl]-N,N-diethyl-  
benzamide**

<sup>1</sup>HNMR (400 MHz, CDCl<sub>3</sub>) δ 7.32 (d, 2H), 7.02 (t, 1H), 6.80 (d, 1H), 6.53 (d, 1H), 3.50  
(br, 2H), 2.42 (br, 1H), 1.56-1.51 (comp; 2H), 1.00-0.90 (comp, 1H), 0.51 (d, 2H); MS (M+1)  
407.1.

30 **N,N-Diethyl-4-[3-(3-hydroxy-phenyl)-1-thiazol-2-ylmethyl-piperidin-3-yl]-  
benzamide**

<sup>1</sup>HNMR (400 MHz, CDCl<sub>3</sub>) δ 7.68 (d, H), 7.07 (t, 1H), 6.80-6.75 (comp, 2H), 6.61 (dd,  
1H), 6.40 (br, 1H), 3.51 (br, 2H) 2.54 (comp, 2H), 2.21 (br, 2H), 1.60-1.50 (comp, 2H); MS  
(M+1) 450.2.

35 **4-[1-Cyclohex-3-enylmethyl-3-(3-hydroxy-phenyl)-piperidin-3-yl]-N,N-diethyl-  
benzamide**

<sup>1</sup>HNMR (400 MHz, CDCl<sub>3</sub>) δ 7.32 (d, 2H), 7.05 (t, 1H), 6.81 (d, 1H), 6.74 (d, 1H), 6.58  
(dd, 1H), 3.50 (br, 2H), 1.89-1.80 (comp, 2H), 1.70-1.63 (comp; 1H), 1.54-1.42 (comp, 2H),  
1.20 (br, 3H); MS (M+1) 447.2

40 **4-[1-Butyl-3-(3-hydroxy-phenyl)-piperidin-3-yl]-N,N-diethyl-benzamide**

- 5 <sup>1</sup>HNMR (400 MHz, CDCl<sub>3</sub>) δ 7.30 (d, 2H), 7.05 (t, 1H), 6.80 (d, 1H), 6.70 (s, 1H), 6.56 (dd, 1H), 3.50 (br, 2H), 2.93 (br, 1H), 2.69 (br, 1H), 2.35-2.30 (comp, 3H), 1.54-1.42 (comp, 5H), 0.91 (t, 3H); MS (M+1) 409.3

**N,N-Diethyl-4-[3-(3-hydroxy-phenyl)-1-(1H-imidazol-2-ylmethyl)-piperidin-3-yl]-benzamide**

- 10 <sup>1</sup>HNMR (400 MHz, CDCl<sub>3</sub>) δ 7.17-7.12 (comp, 4H), 6.87 (s, 2H), 6.65 (d, 1H), 6.52 (d, 1H), 3.53 (br, 2H), 3.27-3.15 (comp, 4H), 2.60-2.50 (comp, 2H), 1.46 (br, 2H); MS (M+1) 433.3

**N,N-Diethyl-4-[3-(3-hydroxy-phenyl)-1-propyl-piperidin-3-yl]-benzamide**

- 15 <sup>1</sup>HNMR (400 MHz, CDCl<sub>3</sub>) δ 7.31 (d, 2H), 7.04 (t, 1H), 6.80 (d, 1H), 6.71 (s, 1H), 6.56 (dd, 1H), 3.50 (br, 2H), 2.49 (br, 1H), 2.20 (br, 2H), 1.62-1.50 (comp, 4H), 0.90 (t, 3H); MS (M+1) 395.3

**N,N-Diethyl-4-[3-(3-hydroxy-phenyl)-1-(3-methyl-butyl)-piperidin-3-yl]-benzamide**

- 20 <sup>1</sup>HNMR (400 MHz, CDCl<sub>3</sub>) δ 7.31 (d, 2H), 7.04 (t, 1H), 6.80 (d, 1H), 6.69 (s, 1H), 6.55 (dd, 1H), 3.50 (br, 2H), 2.51 (br, 1H), 2.39-2.24 (comp, 3H), 1.10 (br, 3H), 0.90 (d, 6H); MS (M+1) 423.3

**{4-[1-Cyclopropylmethyl-3-(3-hydroxy-phenyl)-piperidin-3-yl]-phenyl}-piperidin-1-yl-methanone**

- 25 <sup>1</sup>HNMR (400 MHz, CDCl<sub>3</sub>) δ 7.33-7.30 (comp, 2H), 7.07 (t, 1H), 6.80 (d, 1H), 6.76 (s, 1H), 6.61 (dd, 1H), 3.65 (br, 2H), 3.33 (br, 2H), 2.37 (d, 2H), 2.24 (br, 2H), 1.05-0.94 (comp, 1H), 0.55 (d, 2H), 0.15 (d, 2H); MS (M+1) 419.3.

**4-[1-Allyl-3-(3-hydroxy-phenyl)-piperidin-3-yl]-N,N-diethyl-benzamide**

- <sup>1</sup>HNMR (400 MHz, CDCl<sub>3</sub>) δ 7.28 (comp, 2H), 7.04 (t, 1H), 6.78 (d, 1H), 6.68 (s, 1H), 6.56 (dd, 1H), 6.00-5.89 (comp, 1H), 5.18 (d, 1H), 5.15 (s, 1H), 3.50 (br, 2H), 2.50 (br, 1H), 2.39 (br, 1H), 1.60-1.47 (comp, 2H); MS (M+1) 393.2.

- 30 **N,N-Diethyl-4-[3-(3-hydroxy-phenyl)-1-thiophen-3-ylmethyl-piperidin-3-yl]-benzamide**

<sup>1</sup>HNMR (400 MHz, CDCl<sub>3</sub>) δ 7.09-7.05 (comp, 2H), 7.01 (t, 1H), 6.70 (d, 1H), 6.65 (s, 1H), 6.56 (dd, 1H), 3.49 (br, 4H), 2.37 (br, 1H), 2.18 (br, 2H), 1.58-1.44 (comp, 2H); MS (M+1) 449.3.

- 35 **4-[1-Acetyl-3-(3-hydroxy-phenyl)-piperidin-3-yl]-N,N-diethyl-benzamide**

<sup>1</sup>HNMR (400 MHz, CDCl<sub>3</sub>) δ 7.28-7.20 (comp, 4H), 7.07 (t, 1H), 6.84 (s, 1H), 6.72 (dd, 1H), 6.66 (dd, 1H), 4.18 (d, 1H), 3.85 (d, 1H), 3.21 (br, 2H), 2.04 (s, 3H), 1.59-1.47 (comp, 2H); MS (M+1) 395.2.

**4-[1-But-2-enyl-3-(3-hydroxy-phenyl)-piperidin-3-yl]-N,N-diethylbenzamide**

5 <sup>1</sup>HNMR (400 MHz, CDCl<sub>3</sub>) δ 7.28 (d, 2H), 7.04 (t, 1H), 6.78 (d, 1H), 6.67 (s, 1H), 6.55 (dd, 1H), 5.60-5.57(comp, 2H), 3.50 (br, 2H), 2.36 (br, 1H), 2.21 (br, 2H), 1.60-1.46 (comp, 2H); MS (M+1) 407.3.

**4-[1-Cyclopropylmethyl-3-(4-fluoro-3-hydroxy-phenyl)-piperidin-3-yl]-N,N-diethyl-benzamide**

10 <sup>1</sup>HNMR (400 MHz, CDCl<sub>3</sub>) δ 7.30 (d, 2H), 6.98 (d, 1H), 6.92 (dd, 1H), 6.77 (s, 1H), 3.51 (br, 2H), 2.27 (br, 2H), 1.54 (br, 2H), 0.55 (d, 2H); MS (M+1) 425.5.

**4-[1-Cyclopropylmethyl-3-(3-hydroxy-phenyl)-piperidin-3-yl]-N,N-dimethyl-benzamide**

15 <sup>1</sup>HNMR (400 MHz, CDCl<sub>3</sub>) δ 7.33 (d, 2H), 7.04 (t, 1H), 6.81 (d, 1H), 6.70 (s, 1H), 6.54 (dd, 1H), 3.05 (s, 3H), 2.41 (br, H), 1.60-1.46 (comp, 2H), 0.51 (dd, 2H); MS (M+1) 379.1.

**N,N-Diethyl-4-[3-(3-hydroxy-phenyl)-1-(3,4,4-trifluoro-but-3-enyl)-piperidin-3-yl]-benzamide**

20 <sup>1</sup>HNMR (400 MHz, CDCl<sub>3</sub>) δ 7.31-7.29 (comp, 4H), 7.28-7.19 (comp, 5H), 7.03 (t, 1H), 6.72 (d, 1H), 6.62 (s, 1H), 6.57 (dt 1H), 3.50 (comp, 2H), 3.47 (s, 2H), 3.25 (br, 2H), 2.88 (br, 1H), 2.72 (br, 1H), 2.49 (br, 1H), 2.38 (br, 1H), 2.20 (comp, 2H), 1.51 (comp, 2H), 1.20 (br, 3H), 1.09 (br, 3H); MS (M+1) 443.3.

**4-[1-Cyclopropylmethyl-3-(3-hydroxy-phenyl)-piperidin-3-yl]-N-ethyl-N-methyl-benzamide**

25 <sup>1</sup>HNMR (400 MHz, CDCl<sub>3</sub>) δ 7.33 (d, 2H), 7.05 (t, 1H), 6.82 (d, 1H), 6.72 (s, 1H), 6.56 (d, 1H), 2.42 (br, 1H), 2.32-1.17 (comp, 4H), 1.62-1.48 (comp, 2H), 0.53 (dd, 2H); MS (M+1) 393.1.

**N,N-Diethyl-4-[3-(3-hydroxy-phenyl)-1-(2-oxo-butyl)-piperidin-3-yl]-benzamide**

<sup>1</sup>HNMR (400 MHz, CDCl<sub>3</sub>) δ 7.33-7.26 (comp, 1H), 7.05 (t, 1H), 6.73 (d, 1H), 3.50 (br, 2H), 3.15-3.05 (comp, 1H), 2.24 (br, 1H), 2.11 (d, 4H); MS (M+1) 423.1.

30 **4-[1-Benzyl-3-(3-fluoro-5-hydroxy-phenyl)-piperidin-3-yl]-N,N-diethyl-benzamide**

<sup>1</sup>HNMR (400 MHz, CDCl<sub>3</sub>) δ 6.49 (d, 1H), 6.38 (s, 1H), 6.29 (dt 1H), 3.49 (comp, 2H), 3.45 (comp, 2H), 3.25 (br, 2H); MS (M+1) 461.3.

**4-[1-Cyclopropylmethyl-3-(3-fluoro-5-hydroxy-phenyl)-piperidin-3-yl]-N,N-diethyl-benzamide**

35 <sup>1</sup>HNMR (400 MHz, CDCl<sub>3</sub>) δ 7.29-7.27 (comp, 2H), 7.23-7.20 (comp, 2H), 6.59 (d, 1H), 6.45 (s, 1H), 6.23 (dt, 1H), 3.50 (br, 2H), 3.26 (br, 2H), 2.24 (d, 2H), 2.15 (br, 2H), 0.52 (comp, 2H), 0.10 (comp, 2H), 2.40 (br, 1H), 2.24 (comp, 2H), 1.53 (comp, 2H), 1.20 (br, 3H), 1.10 (br, 3H); MS (M+1) 425.3.

**N,N-Diethyl-4-[3-(3-fluoro-5-hydroxy-phenyl)-1-propyl-piperidin-3-yl]-benzamide**

5 <sup>1</sup>HNMR (400 MHz, CDCl<sub>3</sub>) δ 6.57 (d, 1H), 6.43 (s, 1H), 6.25 (dt, 1H), 3.50 (br, 2H), 3.25 (br, 2H), 2.41 (br, 2H), 2.27 (t, 2H) 2.13 (br, 2H); MS (M+1) 413.3.

**N,N-Diethyl-4-[1-(5-fluoro-pyrimidin-2-yl)-3-(3-hydroxy-phenyl)-piperidin-3-yl]-benzamide**

10 <sup>1</sup>HNMR (400 MHz, CDCl<sub>3</sub>) δ 8.22 (s, 2H), 7.30-7.27 (comp, 2H), 7.05 (t, 1H), 6.83 (d, 1H), 6.74 (t, 1H), 4.21 (q, 2H), 3.82-3.75 (comp, 1H), 3.65-3.59 (comp, 2H), 3.49 (br, 2H), 2.41 (comp, 2H); MS (M+1) 449.3.

**N,N-Diethyl-4-[3-(3-hydroxy-phenyl)-1-pyrimidin-2-yl-piperidin-3-yl]-benzamide**

<sup>1</sup>HNMR (400 MHz, CDCl<sub>3</sub>) δ 8.34 (s, 2H), 7.05 (comp, 1H), 6.81 (d, 2H), 6.55 (d, 2H), 3.82 (comp, 1H), 3.72 (comp, 1H), 2.43 (br, 2H); MS (M+1) 431.3.

15 **{4-[1-Cyclopropylmethyl-3-(3-hydroxy-phenyl)-piperidin-3-ylphenyl]-(3,4-dihydro-1H-isoquinolin-2-yl)-methanone**

<sup>1</sup>HNMR (400 MHz, CDCl<sub>3</sub>) δ 7.28 (d, 2H), 7.05 (t, 1H), 6.75 (d, 1H), 6.72 (s, 1H), 6.59 (dd, 1H), 6.07 (br, 1H), 3.50 (br, 2H), 3.13 (d, 1H), 2.79-2.63 (comp, 1H), 2.18 (br, 2H), 1.21 (br, 3H); MS (M+1) 435.3.

20 **N,N-Diethyl-4-[3-(3-hydroxy-phenyl)-1-(2,2,2-trifluoro-ethyl)-piperidin-3-yl]-benzamide**

<sup>1</sup>HNMR (400 MHz, CDCl<sub>3</sub>) δ 7.38 (d, 2H), 7.27-7.19 (comp, 4H), 7.17 (t, 1H), 6.74 (s, 1H), 6.60 (dd, 1H), 2.38-2.20 (comp, 4H), 1.57 (br, 2H), 0.54 (d, 2H); MS (M+1) 435.3.

#### **EXAMPLE 5**

25 **4-[1-BENZYL-3-(3-CARBOXYAMINO-PHENYL)-PIPERIDIN-3-YL]-N,N-DIETHYL-BENZAMIDE**

**A. Trifluoro-methanesulfonic acid 3-[1-benzyl-3-(4-diethylcarbamoyl-phenyl)-piperidin-3-yl]-phenyl ester**

To a solution of 4-[1-benzyl-3-(3-hydroxy-phenyl)-piperidin-3-yl]-N,N-diethyl-  
30 benzamide (0.92 g, 2.08 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (15 ml) at 0°C was added pyridine (0.25mL, 3.12 mmol) followed by dropwise addition of triflic anhydride (0.52 mL, 3.61mmol) over 5 minutes. The reaction mixture was stirred at 0°C for 1 hour and at room temperature for 2 hours. The solution was then cooled to 0°C and 15 mL of cold saturated aqueous NaHCO<sub>3</sub> were added. The organic layer was separated and the aqueous layer was washed with CH<sub>2</sub>Cl<sub>2</sub> (3 x 20 mL).  
35 The combined organic layers were dried (MgSO<sub>4</sub>) and concentrated. The crude residue was purified by flash chromatography with hexanes/EtOAc (4:1) to afford 0.50 g of trifluoro-methanesulfonic acid 3-[1-benzyl-3-(4-diethylcarbamoyl-phenyl)-piperidin-3-yl]-phenyl ester. <sup>1</sup>HNMR (400 MHz, CDCl<sub>3</sub>) δ 7.39-7.18 (comp, 12H), 7.04-6.99 (m, 1H), 3.60-3.39 (comp, 4H), 3.35-3.28 (comp, 2H), 3.06-2.87 (m, 1H), 2.68-2.44 (comp, 2H), 2.38-2.25 (m, 1H), 2.23-1.96

5 (comp, 2H), 1.64-1.39 (comp, 2H), 1.25-1.11 (comp, 3H), 1.10-0.99 (comp, 3H); MS (M+1) 575.2.

**B. 4-[1-Benzyl-3-(3-cyano-phenyl)-piperidin-3-yl]-N,N-diethyl-benzamide**

To a solution of trifluoro-methanesulfonic acid 3-[1-benzyl-3-(4-diethylcarbamoyl-phenyl)-piperidin-3-yl]-phenyl ester (0.40 g, 0.69 mmol) in DMF (8 mL) was added zinc  
10 cyanide (0.057 g, 0.49 mmol) and tetrakis triphenylphosphine palladium (0.16 g, 0.14 mmol). The reaction was stirred under a nitrogen atmosphere at 90°C for 5 hours. The mixture was cooled to room temperatures and it was diluted with diethyl ether (30 mL). The organic layer was washed with brine (5x 10 mL), dried (MgSO<sub>4</sub>) and concentrated. Purification with hexanes/EtOAc (1:1) afforded 0.28 g of 4-[1-benzyl-3-(3-cyano-phenyl)-piperidin-3-yl]-N,N-  
15 diethyl-benzamide. <sup>1</sup>HNMR (400 MHz, CDCl<sub>3</sub>) δ 7.66 (s, 1H), 7.69-7.20 (comp, 10H), 7.15-7.13 (comp, 2H) 3.60-3.38 (comp, 4H), 3.31-3.19 (comp, 2H), 3.09-2.94 (m, 1H), 2.58-2.45 (comp, 2H), 2.22-2.17 (comp, 3H), 1.71-1.61 (m, 1H), 1.28-1.16 (comp, 3H), 1.17-1.08 (comp, 3H); MS (M+1) 452.2.

**C. 4-[1-Benzyl-3-(3-carboxyamino-phenyl)-piperidin-3-yl]-N,N-diethyl-benzamide**

To a solution of 4-[1-benzyl-cyano-phenyl)-piperidin-3-yl]-N,N-diethyl-  
20 benzamide(0.50g, 1.11 mmol) in ethanol (5 mL) was added 3N aqueous Na<sub>2</sub>CO<sub>3</sub> (3.25 mL) and 30% aqueous H<sub>2</sub>O<sub>2</sub> (0.88mL). The reaction mixture was stirred at room temperature for 8 hours. The mixture was diluted with water (2 mL) and the aqueous layer was washed with CH<sub>2</sub>Cl<sub>2</sub> (3x10 mL). The organic layer was dried (MgSO<sub>4</sub>) and concentrated. The residue was  
25 purified by flash chromatography with CH<sub>2</sub>Cl<sub>2</sub>/methanol (MeOH) (10:1) to afford 0.42 mg of . <sup>1</sup>HNMR (400 MHz, CDCl<sub>3</sub>) δ 7.80 (s, 1H), 7.56 (d, 1H), 7.40-7.16 (comp, 11H), 5.99 (br, 1H), 5.59 (br, 1H), 3.59-3.39 (comp, 4H), 3.34-3.18 (comp, 2H), 3.06-2.88 (m, 1H), 2.81-2.62 (m; 1H), 2.41-2.27 (m, 1H), 2.25-2.17 (comp, 3H), 2.58-2.41 (comp, 2H), 1.28-1.18 (comp, 3H), 1.17-1.00 (comp, 3H) MS (M+1) 470.3.

30 The following examples were prepared by methods similar to those described above in Example 5.

**4-[1-(2,2,2-trifluoroethyl)-3-(3-carboxyamino-phenyl)-piperidin-3-yl]-N,N-diethyl-benzamide**

<sup>1</sup>HNMR (400 MHz, CDCl<sub>3</sub>) δ 7.93 (s, 1H), 7.64-7.61 (m, 1H), 6.24 (br, 1H), 3.56-3.42  
35 (comp, 2H), 2.62 (t, 1H), 1.18-1.10 (comp, 3H); MS (M+1) 462.3.

**N,N-Diethyl-4-[3-(3-carboxyamino-phenyl)-1-thiazol-2-ylmethyl-piperidin-3-yl]-benzamide**

<sup>1</sup>HNMR (400 MHz, CDCl<sub>3</sub>) δ 8.15 (s, 1H), 7.72 (d, 1H), 7.68-7.65 (m, 1H), 5.93 (br, 1H), 2.77-2.67 (comp, 2H), 1.08 (comp, 3H); MS (M+1) 477.3.

40 **N,N-Diethyl-4-[1-furan-2-ylmethyl-3-(3-carboxyamino-phenyl)-piperidin-3-yl]-benzamide**

- 5 <sup>1</sup>HNMR (400 MHz, CDCl<sub>3</sub>) δ 7.92 (s, 1H), 7.61 (d, 1H), 6.23 (br, 1H), 3.27-3.21 (comp, 2H), 1.18-1.01 (comp, 3H); MS (M+1) 460.3.

#### EXAMPLE 6

##### 1-CYCLOPROPYLMETHYL-3-(3-METHOXY-PHENYL)-3-(4-THIOPHEN-2-YL-PHENYL)-PIPERIDINE

- 10 To a solution of trifluoro-methanesulfonic acid 4-[1-cyclopropylmethyl-3-(3-methoxy-phenyl)-piperidin-3-yl]-phenyl ester (0.1 g, 0.2 mmol) in ethanol (4.5 mL) and water (0.5 mL) was added 2-thiophene boronic acid (0.052 g, 0.5 mmol) and sodium carbonate (0.037 g, 0.29 mmol) and tetrakis triphenylphosphine palladium (0.02 g, 0.18 mmol). The reaction mixture was heated to reflux for 2 hours. The mixture was then filtered and the filtrate was
- 15 concentrated under vacuum. The residue was purified by flash chromatography with hexanes/EtOAc (3:1) to afford 0.08 g of 1-cyclopropylmethyl-3-(3-methoxy-phenyl)-3-(4-thiophen-2-yl-phenyl)-piperidine. <sup>1</sup>HNMR (400 MHz, CDCl<sub>3</sub>) δ 7.49 (d, 2H), 7.35 (d, 2H), 7.22-7.06 (comp, 3H), 7.05-7.00 (m, 1H), 6.96 (s, 1H), 6.89 (d, 1H), 6.70-6.67 (m, 1H), 3.76 (s, 3H), 3.17-2.82 (comp, 2H), 2.61-2.39 (comp, 2H), 2.27-2.18 (comp, 4H), 1.62-1.39 (comp, 3H),
- 20 0.60-0.45 (comp, 2H), 0.18-0.11 (comp, 2H); MS (M+1) 404.2.

#### EXAMPLE 7

##### 3-[4-[1-ALLYL-3-(3-METHOXY-PHENYL)-PIPERIDIN-3-YL]-PHENYL]-PENTAN-3-OL

- To a solution of 4-[1-allylmethyl-3-(3-methoxy-phenyl)-piperidin-3-yl]-benzoic acid
- 25 methyl ester (1.71 g, 4.68 mmol) in THF (30 mL) at 0°C was added ethylmagnesium bromide (1M in tert-butylmethylether, 46.8 mL, 46.8 mmol). The ice bath was removed and the reaction was stirred at room temperature for 1 hour. The mixture was quenched with slow addition of water (15 mL). The aqueous layer was washed with diethyl ether (3x 30 mL). The combined extracts were dried (MgSO<sub>4</sub>) and concentrated to afford 1.67g (91%) of 3-[4-[1-
- 30 allyl-3-(3-methoxy-phenyl)-piperidin-3-yl]-phenyl]-pentan-3-ol. <sup>1</sup>HNMR (400 MHz, CDCl<sub>3</sub>) δ 7.23-7.20 (comp, 5H), 7.15 (t, 1H), 6.85-6.84 (comp, 2H), 6.66 (dd, 1H), 6.01-5.92 (m, 1H), 5.20 (s, 1H), 5.17-5.14 (m, 1H), 3.71 (s, 3H), 3.04-2.95 (comp, 2H), 2.88-2.72 (comp, 2H), 2.50-2.40 (comp, 2H), 2.27-2.21 (comp, 2H), 1.83-1.71 (comp, 4H), 1.57-1.49 (comp, 2H), 0.71 (dt, 6H); MS (M+1) 394.3.

- 35 The following compounds were prepared by a procedure analogous to that of Example 4 for the deprotection of methyl ethers.

##### 3-[1-Allyl-3-[4-(1-ethyl-1-hydroxy-propyl)-phenyl]-piperidin-3-yl]-phenol

- <sup>1</sup>HNMR (400 MHz, CDCl<sub>3</sub>) δ 7.21 (s, 5H), 7.09 (t, 1H), 6.84 (d, 1H), 6.73 (s, 1H), 6.55 (dd, 1H), 6.02-5.92 (m, 1H), 5.20-5.14 (comp, 2H), 3.07-2.96 (comp, 2H), 2.88-2.82 (comp, 2H), 2.50-2.40 (comp, 2H), 2.25-2.20 (comp, 2H), 1.82-1.72 (comp, 4H), 1.65 (br, 1H), 1.61-1.52 (comp, 2H), 0.71 (t, 6H); MS (M+1) 380.3.
- 40

5           3-{3-[4-(1-Ethyl-1-hydroxy-propyl)-phenyl]-1-(2,2,2-trifluoro-ethyl)-piperidin-3-yl]-phenol

<sup>1</sup>HNMR (400 MHz, CDCl<sub>3</sub>) δ 6.84 (dd, 1H), 6.79 (t, 1H), 4.97 (br, 1H), 2.23-2.20 (comp, 2H), 0.72 (t, 6H); MS (M+1) 422.2.

10           3-{3-[4-(1-Ethyl-1-hydroxy-propyl)-phenyl]-3,4,5,6-tetrahydro-2H-[1,2]bipyridinyl-3-yl]-phenol

<sup>1</sup>HNMR (400 MHz, CDCl<sub>3</sub>) δ 8.17-8.16 (m, 1H), 7.07 (t, 1H), 6.71 (d, 1H), 4.25 (d, 1H), 3.96 (d, 1H), 2.47-2.35 (comp, 2H); MS (M+1) 417.3.

15           3-{1-Cyclopropylmethyl-3-[4-(1-ethyl-1-hydroxy-propyl)-phenyl]-piperidin-3-yl}-phenol

<sup>1</sup>HNMR (400 MHz, CDCl<sub>3</sub>) δ 7.10 (t, 1H), 6.80 (d, 1H), 6.64 (d, 1H), 2.32 (br, 1H), 2.24 (br, 1H), 0.58 (d, 2H); MS (M+1) 394.4.

The following compounds were made using the procedure of Example 7 followed by conversion of R<sup>3</sup>=OH to R<sup>3</sup>=CONH<sub>2</sub> according to the procedure of Example 5.

20           3-{1-Allyl-3-[4-(1-ethyl-1-hydroxy-propyl)-phenyl]-piperidin-3-yl}-benzamide

<sup>1</sup>HNMR (400 MHz, CDCl<sub>3</sub>) δ 7.83 (s, 1H), 7.54 (d, 1H), 7.40 (d, 1H), 7.30 (t, 1H), 7.24-7.15 (comp, 4H), 6.06-5.94 (comp, 2H), 5.56 (br, 1H), 5.21-5.16 (comp, 2H), 3.00 (d, 2H), 2.69 (br, 1H), 2.56 (br, 1H), 2.42-2.28 (comp, 2H), 2.27-2.20 (m, 1H), 1.82-1.70 (comp, 4H), 1.64 (br, 1H), 1.60-1.42 (comp, 2H), 0.71 (dt, 6H); MS (M+1) 407.3.

25           3-{3-[4-(1-Ethyl-1-hydroxy-propyl)-phenyl]-3,4,5,6-tetrahydro-2H-[1,2]bipyridinyl-3-yl}-benzamide

<sup>1</sup>HNMR (400 MHz, CDCl<sub>3</sub>) δ 8.22 (d, 1H), 8.11 (s, 1H), 7.31 (t, 1H), 2.63-2.57 (comp, 2H), 2.52-2.39 (comp, 2H), 0.69 (t, 6H); MS (M+1) 444.3.

30           3-{3-[4-(1-Ethyl-1-hydroxy-propyl)-phenyl]-1-(2,2,2-trifluoro-ethyl)-piperidin-3-yl}-benzamide

<sup>1</sup>HNMR (400 MHz, CDCl<sub>3</sub>) δ 7.95 (s, 1H), 7.23 (d, 2H), 7.15 (d, 2H), 5.62 (br, 1H), 2.86 (d, 2H), 2.60-2.54 (m, 1H), 0.71 (t, 6H); MS (M+1) 431.3.

#### EXAMPLE 8

#### PROPIONIC ACID 3-(1-CYCLOPROPYLMETHYL-3-P-TOLYL-PIPERIDIN-3-YL)-PHENYL ESTER

35           To a solution of 3-(1-cyclopropylmethyl-3-p-tolyl-piperidin-3-yl)-phenol (65 mg, 0.15 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (2 ml) at room temperature were added DMAP (18 mg, 0.15 mmol), triethylamine (0.071 mL, 0.52 mmol) and propionyl chloride (0.038 mL, 0.45 mmol). The reaction mixture was stirred at room temperature for 12 hours. The reaction was partitioned between 5 mL CH<sub>2</sub>Cl<sub>2</sub> and 5 mL of aqueous saturated NaHCO<sub>3</sub>. The aqueous layer was washed with CH<sub>2</sub>Cl<sub>2</sub> (3x5 mL), dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated. Purification by flash chromatography with hexanes/EtOAc (1:1) afforded 58 mg of propionic acid 3-(1-

40



5 cyclopropylmethyl-3-p-tolyl-piperidin-3-yl)-phenyl ester. <sup>1</sup>HNMR (400 MHz, CDCl<sub>3</sub>) δ 7.33 (d, 2H), 7.26-7.19 (comp, 3H), 7.16-7.03 (comp, 2H), 6.89-6.86 (m, 1H), 3.59-3.43 (comp, 2H), 3.35-3.19 (comp, 2H), 2.59-2.53 (q, 2H), 2.52-2.41 (comp, 2H), 2.27-2.18 (comp, 4H), 1.57-1.44 (comp, 2H), 1.31-1.19 (t, 3H), 1.18-1.09 (comp, 3H), 1.08-1.01 (comp, 3H), 1.00-0.91 (m, 1H), 0.59-0.49 (comp, 2H), 0.19-0.11 (comp, 1H); MS (M+1) 463.3.

10 The following compound was made using a procedure similar to that of Example 8.

**Isobutyric acid 3-[1-cyclopropylmethyl-3-(4-diethylcarbamoyl-phenyl)-piperidin-3-yl]-phenyl ester**

<sup>1</sup>HNMR (400 MHz, CDCl<sub>3</sub>) δ 7.36-7.29 (comp, 2H) 7.10-7.02 (comp, 2H), 6.89-6.85 (m, 1H), 3.01-2.82 (comp, 2H), 2.81-2.75 (m, 1H), 1.28 (d, 3H); MS (M+1) 477.3.

15

#### EXAMPLE 9

#### 4-[4-CYCLOPROPYLMETHYL-2-(3-HYDROXY-PHENYL)-MORPHOLIN-2-YL]-N,N-DIETHYLBENZAMIDE

##### **A. (4-Bromo-phenyl)-(3-methoxy-phenyl)-methanol**

To a suspension of magnesium (2.4 g, 100 mmol), in THF (20 mL) at room temperature was added dropwise a solution of bromoanisole (9.1 mL, 71.4 mmol) in THF (30 mL). The reaction mixture was stirred at room temperature for 2 h and at 60°C for 2 h. The mixture was cooled to room temperature and a solution of 4-bromobenzaldehyde (13.2 g, 71.4 mmol) was added over 5 min. The reaction mixture was stirred at room temperature for 3 h and was quenched by addition of aqueous saturated ammonium chloride (NH<sub>4</sub>Cl) (30 mL).  
25 The aqueous layer was washed with ether (3x40 mL), dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated. Purification by flash chromatography with hexanes/EtOAc (10:1) afforded 16.95 g of (4-bromo-phenyl)-(3-methoxy-phenyl)-methanol. <sup>1</sup>HNMR (400 MHz, CDCl<sub>3</sub>) δ 7.46-7.41 (comp, 2H), 7.27-7.18 (comp, 3H), 6.91-6.87 (comp, 2H), 6.81-6.78 (m, 1H), 5.73 (s, 1H), 3.76 (s, 3H); MS (M+1) 294.2.

30

##### **B. (4-Bromo-phenyl)-(3-methoxy-phenyl)-methanone**

To a solution of DMSO (8.13 mL, 114.7 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (80 mL) at -78 was added solution of trifluoroacetic acid (TFAA) (12.12 mL, 86.0 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (50 mL) over 5 min. The mixture was stirred for 20 min and a solution of (4-bromo-phenyl)-(3-methoxy-phenyl)-methanol (16.8 g, 57.4 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (50 mL) was added dropwise over 5 min. The reaction mixture was stirred at -78°C for 30 min and Et<sub>3</sub>N (24.0 mL, 172 mmol) was added.  
35 The mixture was stirred at -78°C for an additional 30 min and at room temperature for 1 h. The CH<sub>2</sub>Cl<sub>2</sub> layer was washed with brine (3x30 mL), dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated. Purification with hexanes /EtOAc (10:1) afforded 16.0 g of (4-Bromo-phenyl)-(3-methoxy-phenyl)-methanone. <sup>1</sup>HNMR (400 MHz, CDCl<sub>3</sub>) δ 7.67-7.66 (comp, 2H), 7.64-7.60 (comp, 2H),  
40 7.37 (m, 1H), 7.34-7.27 (comp, 2H), 7.14-7.11 (m, 1H), 3.84 (s, 3H).

##### **C. 2-Amino-1-(4-bromo-phenyl)-1-(3-methoxy-phenyl)-ethanol**

5 To a solution of (4-bromo-phenyl)-(3-methoxy-phenyl)-methanone (2.06 g, 7.07 mmol), in  $\text{CH}_2\text{Cl}_2$  (3.5 mL) at room temperature was added  $\text{ZnI}_2$  (0.15 g, 0.47 mmol) followed by addition of TMSCN (4.29 mL, 32.2 mmol). The reaction mixture was stirred at room temperature for 3 h and was quenched by addition of brine (20 mL). The aqueous layer was washed with  $\text{CH}_2\text{Cl}_2$  (3x30 mL) and the combined organic extracts were dried over  $\text{Na}_2\text{SO}_4$  and concentrated to afford an oil. The resulting oil was dissolved in THF (7 mL) and the solution was added dropwise to a solution of lithium aluminum hydride (LAH) in THF (1M, 8.13 mL) at 0°C. The mixture was stirred at 0°C for 1 h and at room temperature for 1 h. To the solution was added  $\text{H}_2\text{O}$  (1.5 mL) followed by addition of 15% aqueous sodium hydroxide (NaOH) (1.5 mL) and  $\text{H}_2\text{O}$  (4.5 mL). The mixture was filtered through celite and the celite was washed with EtOAc (20 mL). The filtrate was dried over  $\text{MgSO}_4$  and concentrated. Purification by flash chromatography with  $\text{CH}_2\text{Cl}_2/\text{MeOH}$  (20:1) afforded 2.1 g of 2-amino-1-(4-bromo-phenyl)-1-(3-methoxy-phenyl)-ethanol.  $^1\text{H}$ NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.44-7.40 (comp, 2H), 7.33-7.26 (comp, 2H), 7.24-7.20 (m, 1H), 7.01-6.99 (m, 1H), 6.97-6.94 (m, 1H), 3.77 (s, 3H), 3.47-3.35 (comp, 2H), 3.29-3.24 (comp, 2H); MS (M+1) 304.1, 306.1.

20 **D. N-[2-(4-Bromo-phenyl)-2-hydroxy-2-(3-methoxy-phenyl)-ethyl]-2-chloro-acetamide**

To a solution of 2-amino-1-(4-bromo-phenyl)-1-(3-methoxy-phenyl)-ethanol (0.94 g, 2.92 mmol) in toluene (10 mL) at 0°C was added triethylamine (0.41 mL, 3.07 mmol). To the reaction mixture was added a solution of chloroacetylchloride (0.23 mL, 2.92 mmol) in toluene (1 mL) and the reaction was stirred at 0°C for 30 min. and at room temperature for 1 h. To the reaction was added cold water (10 mL) and the mixture was stirred for 10 min. EtOAc was added (20 mL) and the layers were separated. The aqueous layer was washed with EtOAc (2x20 mL) and the combined organic extracts were dried over  $\text{MgSO}_4$ , and concentrated. Purification by flash chromatography with hexanes/EtOAc (4:1) afforded 1.08 g of N-[2-(4-bromo-phenyl)-2-hydroxy-2-(3-methoxy-phenyl)-ethyl]-2-chloro-acetamide.  $^1\text{H}$ NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.45-7.41 (comp, 2H), 7.29-7.20 (comp, 3H), 6.97-6.96 (m, 1H), 6.93-6.90 (m, 1H), 6.86-6.85 (m, 1H), 6.85-6.79 (m, 1H), 4.14-3.98 (comp, 2H), 3.95 (s, 2H), 3.77 (s, 3H); MS (M+1) 380.0, 382.0.

**E. 6-(4-Bromo-phenyl)-6-(3-methoxy-phenyl)-morpholin-3-one**

35 To a solution of N-[2-(4-bromo-phenyl)-2-hydroxy-2-(3-methoxy-phenyl)-ethyl]-2-chloro-acetamide (3.67 g, 9.2 mmol), in benzene (205 mL) at room temperature was added t-BuOK (4.54 g, 40.5 mmol). The reaction mixture was stirred at room temperature for 2 h. To the mixture was added water (40 mL) and the aqueous layer was washed with  $\text{CH}_2\text{Cl}_2$  (2x50 mL). The combined organic extracts were dried over  $\text{MgSO}_4$  and concentrated. Purification by flash chromatography with hexanes/EtOAc (3:1) afforded 3.34 g of 6-(4-bromo-phenyl)-6-(3-methoxy-phenyl)-morpholin-3-one.  $^1\text{H}$ NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.46-7.41 (comp, 2H), 7.27-

- 5 7.17 (comp, 2H), 6.89-6.70 (comp, 3H), 6.69 (br, 1H), 4.10 (s, 2H), 3.93-3.80 (comp, 2H), 3.76 (s, 3H); MS (M+1) 362.1, 364.1.

**F. 2-(4-Bromo-phenyl)-2-(3-methoxy-phenyl)-morpholine**

- To a solution of LAH in THF (1M, 13.9 mL) at 0°C was added a solution of 6-(4-bromo-phenyl)-6-(3-methoxy-phenyl)-morpholin-3-one (3.34 g, 9.23 mmol) in THF (15 mL).  
10 The reaction mixture was stirred at 0°C for 1 h and at room temperature for 16 h. To the mixture was added H<sub>2</sub>O (6.2 mL) followed by addition of 15% aqueous NaOH (6.2 mL) and H<sub>2</sub>O (7 mL). The mixture was filtered through celite and the celite was washed with EtOAc (50 mL). The filtrate was dried over MgSO<sub>4</sub> and concentrated to afford 2.82 g of 2-(4-bromo-phenyl)-2-(3-methoxy-phenyl)-morpholine. <sup>1</sup>HNMR (400 MHz, CDCl<sub>3</sub>) δ 7.43-7.36 (comp, 2H),  
15 7.33-7.20 (comp, 3H), 6.98-6.82 (comp, 2H), 6.79-6.75 (m, 1H), 3.76 (s, 3H), 3.68-3.69 (comp, 2H), 3.45-3.29 (comp, 2H), 2.93-2.88 (comp, 2H); MS (M+1) 348.01, 350.0.

**G. 2-(4-Bromo-phenyl)-4-cyclopropylmethyl-2-(3-methoxy-phenyl)-morpholine**

- Prepared by methods similar to those described in Examples 2 and 3. <sup>1</sup>HNMR (400 MHz, CDCl<sub>3</sub>) δ 7.42-7.38 (comp, 2H), 7.30-7.18 (comp, 3H), 7.08-6.97 (m, 1H), 6.96-6.84 (m,  
20 1H), 6.79-6.71 (m, 1H), 3.76 (s, 3H), 3.75-3.61 (comp, 2H), 3.15-2.88 (comp, 2H), 2.59-2.51 (comp, 2H), 2.29-2.19 (comp, 2H), 1.01-0.84 (m, 1H), 0.50-0.49 (comp, 2H), 0.18-0.11 (comp, 2H); MS (M+1) 402.0, 404.0.

**H. 4-[4-Cyclopropylmethyl-2-(3-methoxy-phenyl)-morpholin-2-yl]-benzoic acid methyl ester**

- 25 Prepared by a procedure similar to that described in example 1D. <sup>1</sup>HNMR (400 MHz, CDCl<sub>3</sub>) δ 7.94 (d, 2H), 7.48 (d, 2H), 7.21-7.18 (m, 1H), 6.98 (s, 1H), 6.91 (d, 1H), 6.74 (dd, 1H), 3.87 (s, 3H), 3.75 (s, 3H), 3.74-3.63 (comp, 2H), 3.09-2.92 (comp, 2H), 2.56-2.48 (comp, 2H), 2.31-2.18 (comp, 2H), 0.98-0.88 (m, 1H), 0.59-0.51 (comp, 2H), 0.14-0.10 (comp, 1H); MS (M+1) 382.1.

- 30 **I. 4-[4-Cyclopropylmethyl-2-(3-methoxy-phenyl)-morpholin-2-yl]-N,N-diethylbenzamide**

- Prepared by a method similar to that described in Example 1E. <sup>1</sup>HNMR (400 MHz, CDCl<sub>3</sub>) δ 7.40 (d, 1H), 7.28 (d, 2H), 7.23-7.18 (m, 1H), 7.06-6.98 (m, 1H), 6.93 (d, 1H) 6.75 (dd, 1H), 3.76 (s, 3H), 3.75-3.76 (comp, 2H), 3.55-3.49 (comp, 2H), 3.32-3.19 (comp, 2H),  
35 3.16-3.02 (m, 1H), 2.99-2.84 (m, 1H), 2.58-2.43 (comp, 2H), 2.34-2.26 (m, 1H), 2.25-2.18 (m, 1H), 1.26-1.17 (comp, 3H), 1.16-1.04 (comp, 3H), 0.99-0.90 (m, 1H), 0.59-0.51 (comp, 2H), 0.14-0.10 (comp, 2H); MS (M+1) 423.3.

**J. 4-[4-Cyclopropylmethyl-2-(3-hydroxy-phenyl)-morpholin-2-yl]-N,N-diethylbenzamide**

- 40 Prepared by a method similar to that described in Example 4. <sup>1</sup>HNMR (400 MHz, CDCl<sub>3</sub>) δ 7.38 (d, 1H), 7.26 (d, 2H), 7.12-7.06 (m, 1H), 6.91 (d, 1H), 6.82 (s, 1H), 6.61 (dd,

- 5 1H), 3.79-3.63 (comp, 2H), 3.59-3.42 (comp, 2H), 3.35-3.19 (comp, 2H), 3.08-2.83 (comp, 2H), 2.61-2.44 (comp, 2H), 2.32-2.18 (comp, 2H), 1.29-1.19 (comp, 3H), 1.18-1.01 (comp, 3H), 0.99-0.89 (m, 1H), 0.59-0.49 (comp, 2H), 0.15-0.10 (comp, 2H); MS (M+1) 409.1.

The following examples were prepared by procedures described above in Example 9.

10 **4-[4-Allyl-2-(3-hydroxy-phenyl)-morpholin-2-yl]-N,N-diethyl-benzamide**

<sup>1</sup>HNMR (400 MHz, CDCl<sub>3</sub>) δ 6.81 (s, 1H), 6.02-5.83 (m, 1H), 5.29-5.16 (comp, 2H), 3.04-2.98 (comp, 2H), 2.58-2.43 (comp, 2H); MS (M+1) 395.3.

**4-[4-Benzyl-2-(3-hydroxy-phenyl)-morpholin-2-yl]-N,N-diethyl-benzamide**

- 15 <sup>1</sup>HNMR (400 MHz, CDCl<sub>3</sub>) δ 7.13-7.06 (m, 1H), 6.81-6.75 (comp, 2H), 6.67 (d, 1H), 3.79-3.61 (comp, 2H), 3.32-3.18 (comp, 2H); MS (M+1) 445.3.

The following compound was prepared by the procedure of Example 9 and subsequent conversion of R<sup>3</sup>=OH to R<sup>3</sup>=CONH<sub>2</sub> according to the procedure of Example 5.

**4-[4-Cyclopropylmethyl-2-(3-carboxyamino-phenyl)-morpholin-2-yl]-N,N-diethyl-benzamide**

- 20 <sup>1</sup>HNMR (400 MHz, CDCl<sub>3</sub>) δ 7.91 (s, 1H), 7.70-7.61 (comp, 1H), 3.81-3.63 (comp, 2H), 0.61-0.44 (comp, 2H), 0.21-0.15 (comp, 2H); MS (M+1) 436.3.

**EXAMPLE 10**

**A. (5-Bromo-pyridin-2-yl)-(3-methoxy-phenyl)-acetonitrile**

- 25 To a suspension of hexane washed 60% sodium hydride (2.65, 66.0 mmol) in DMF (30 mL) at 0°C was added 3-methoxyphenyl acetonitrile (8.0 g, 54.3 mmol). The reaction mixture was stirred at 0°C for 30 min. A solution of 2,5-dibromopyridine (15.45g, 65.2 mmol) in DMF(20 mL) was added and the reaction was stirred at room temperature for 20 min and at 50°C for 30 min. To the reaction mixture was added H<sub>2</sub>O (20 mL) and Et<sub>2</sub>O (200 mL). The  
30 organic layer was washed with brine (5x50 mL), dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated. Purification by flash chromatography with hexanes/EtOAc (10:1) afforded 10.6 g of (5-Bromo-pyridin-2-yl)-(3-methoxy-phenyl)-acetonitrile. <sup>1</sup>HNMR (400 MHz, CDCl<sub>3</sub>) δ 8.63 (s,1H), 7.80 (dd, 1H), 7.27 (comp, 2H), 6.98 (d, 1H), 6.87 (s,1H), 6.84 (m, 1H), 5.28 (s, 1H), 5.23 (s, 3H); MS (M+1) 303.0, 305.0.

35 **B. 2-(5-Bromo-pyridin-2-yl)-5-chloro-2-(3-methoxy-phenyl)-pentanenitrile**

- To a suspension of hexane washed 60% sodium hydride (0.35 g, 8.6 mmol) in DMF (2 mL) at 0°C was added a solution of (5-bromo-pyridin-2-yl)-(3-methoxy-phenyl)-acetonitrile (1.75 g, 5.76 mmol) in DMF (5 mL). The reaction mixture was stirred at 0°C for 30 min and at room temperature for 1 h. 1-bromo-3-chloropropane (0.69 mL, 6.91 mmol) was added and  
40 the mixture was stirred at room temperature for 4 h. To the reaction mixture was added H<sub>2</sub>O (5 mL) and Et<sub>2</sub>O and the organic layer was washed with brine (5x5 mL), dried over Na<sub>2</sub>SO<sub>4</sub>

5 and concentrated. Purification by flash chromatography with hexanes/EtOAc (10:1) yielded 1.81 g of 2-(5-bromo-pyridin-2-yl)-5-chloro-2-(3-methoxy-phenyl)-pentanenitrile. <sup>1</sup>HNMR (400 MHz, CDCl<sub>3</sub>) δ 8.65 (s, 1H), 7.76 (dd, 1H), 7.36 (d, 1H), 7.27-7.21 (m, 1H), 7.03 (d, 1H), 6.98 (s, 1H), 6.82 (dd, 1H), 4.77 (s, 3H), 3.55 (t, 2H), 2.79-2.70 (comp, 1H), 2.62-2.52 (comp, 1H) 1.89-1.79 (comp, 2H); MS (M+1) 378.8, 380.8.

10 **C. 5-Bromo-3'-(3-methoxy-phenyl)-1',2',3',4',5',6'-hexahydro-[2,3]bipyridinyl**

To a solution of 2-(5-bromo-pyridin-2-yl)-5-chloro-2-(3-methoxy-phenyl)-pentanenitrile (0.54 g, 1.43 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (3 mL) at -78°C was added DIBAL in CH<sub>2</sub>Cl<sub>2</sub> (1M, 3.2 mL). The reaction mixture was stirred at -78 for 1 h and at room temperature for 4 h. The solution was poured to a saturated aqueous solution of Rochelle's salt (10 mL) and the resulting mixture was stirred vigorously for 16 h. The aqueous layer was washed with CH<sub>2</sub>Cl<sub>2</sub> (3x10 mL), and the combined extracts were dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated. Purification by flash chromatography with CH<sub>2</sub>Cl<sub>2</sub>/MeOH (10:1) yielded 0.36 g of 5-bromo-3'-(3-methoxy-phenyl)-1',2',3',4',5',6'-hexahydro-[2,3]bipyridinyl. <sup>1</sup>HNMR (400 MHz, CDCl<sub>3</sub>) δ 8.62 (s, 1H), 7.63 (dd, 1H), 7.24-7.18(m, 1H), 6.91 (d, 1H) 6.81-6.67 (comp, 3H), 3.96-3.90 (m, 1H), 3.75 (s, 3H), 3.09-3.00 (comp, 2H), 2.82-2.74 (m, 1H), 2.54-2.48 (m, 1H), 2.41-2.34 (m, 1H) 1.64-1.60 (m, 1H) 1.38-1.31 (m, 1H); MS(M+1) 347.1, 349.1.

**D. 5-Bromo-1'-benzyl-3'-(3-methoxy-phenyl)-1',2',3',4',5',6'-hexahydro-[2,3]bipyridinyl**

Prepared by methods similar to those described in Examples 2 and 3.

25 <sup>1</sup>HNMR (400 MHz, CDCl<sub>3</sub>) δ 8.55 (s, 1H), 7.62 (dd, 1H), 7.42-7.21 (comp, 6H), 7.20-7.12 (m, 1H), 7.01 (d, 1H), 6.81-6.74 (m, 1H), 6.67 (dd, 1H) 3.78 (s, 3H), 3.59-3.41 (comp, 2H), 3.20-3.12 (m, 1H), 2.81 -2.25 (comp, 4H), 2.18-2.04 (m, 1H), 1.62-1.41 (comp, 2H); MS(M+1) 437.2, 439.3.

30 **E. 1'-Benzyl-3'-(3-methoxy-phenyl)-1',2',3',4',5',6'-hexahydro-[2,3]bipyridinyl-5-carboxylic acid methyl ester**

Prepared by a method similar to that of Example 1D.

<sup>1</sup>HNMR (400 MHz, CDCl<sub>3</sub>) δ 9.10 (s, 1H), 8.10 (dd, 1H) 7.41-7.01 (comp, 7H), 6.81-6.77 (comp, 2H), 6.67 (dd, 1H), 3.90 (s, 3H), 3.70 (s, 3H), 3.61-3.42 (comp, 2H), 3.25-3.15 (m, 1H), 2.85-2.75 (comp, 2H), 2.61-2.53 (m, 1H), 2.41-2.38 (m, 1H), 2.20-2.12 (m, 1H), 1.62-1.55 (comp, 2H); MS(M+1) 417.2.

**F. 1'-Benzyl-3'-(3-methoxy-phenyl)-1',2',3',4',5',6'-hexahydro-[2,3]bipyridinyl-5-carboxylic acid diethylamide**

Prepared by a method similar to that of Example 1E.

40 <sup>1</sup>HNMR (400 MHz, CDCl<sub>3</sub>) δ 8.53 (s, 1H), 7.55 (dd, 1H), 7.38-7.21 (comp, 5H), 7.18-7.09 (comp, 2H), 6.83-6.78 (comp, 2H), 6.68-6.62 (m, 1H), 3.71 (s, 3H), 3.60-3.42 (comp, 4H),

- 5 3.38-3.22 (comp 2H), 3.18-3.07 (m, 1H), 2.92-2.82 (m, 1H), 2.65-2.61 (m, 1H), 2.58- 2.40 (comp, 2H), 2.18-2.03 (m, 1H), 1.64-1.43 (comp, 2H), 1.34-1.10 (comp, 6H); MS(M+1) 449.3

**G. 1'-Benzyl-3'-(3-hydroxy-phenyl)-1',2',3',4',5',6'-hexahydro-[2,3]bipyridinyl-5-carboxylic acid diethylamide**

- Prepared by a method similar to that of Example 4. <sup>1</sup>HNMR (400 MHz, CDCl<sub>3</sub>) δ 8.53 (s, 1H), 7.55 (d, 1H), 7.40-7.21 (comp, 5H), 7.19-7.08 (m, 1H), 7.03-6.89 (m, 1H), 6.77-6.62 (comp, 2H), 6.58-6.52 (m, 1H), 3.60-3.42 (comp, 4H), 3.36-3.22 (comp, 2H), 3.18-3.04 (m, 1H), 2.82-2.78 (m, 1H), 2.71-2.26 (comp, 3H), 2.18-2.03 (m, 1H), 1.62-1.44 (comp, 2H), 1.35-1.10 (comp, 6H); MS(M+1) 444.2.

- The following compounds were prepared by methods similar to those described in Example 10.

**1'-(5-Fluoro-pyrimidin-2-yl)-3'-(3-hydroxy-phenyl)-1',2',3',4',5',6'-hexahydro-[2,3]bipyridinyl-5-carboxylic acid diethylamide**

<sup>1</sup>HNMR (400 MHz, CDCl<sub>3</sub>) δ 8.20 (s, 2H), 4.57 (d, 1H), 4.17 (d, 1H); MS(M+1) 450.3.

- 3'-(3-Hydroxy-phenyl)-1'-pyrimidin-2-yl-1',2',3',4',5',6'-hexahydro-[2,3]bipyridinyl-5-carboxylic acid diethylamide**

<sup>1</sup>HNMR (400 MHz, CDCl<sub>3</sub>) δ 8.33 (s, 2H), 6.49 (d, 2H), 4.57 (d, 1H), 4.17 (d, 1H); MS(M+1) 432.3.

**1'-Cyclopropylmethyl-3'-(3-hydroxy-phenyl)-1',2',3',4',5',6'-hexahydro-[2,3]bipyridinyl-5-carboxylic acid diethylamide**

- <sup>1</sup>HNMR (400 MHz, CDCl<sub>3</sub>) δ 7.58 (dd, 1H), 1.01-0.84 (m, 1H), 0.57-0.49 (comp, 2H), 0.17-0.11 (comp, 2H); MS(M+1) 408.4.

**3'-(3-Hydroxy-phenyl)-1'-propyl-1',2',3',4',5',6'-hexahydro-[2,3]bipyridinyl-5-carboxylic acid diethylamide**

- <sup>1</sup>HNMR (400 MHz, CDCl<sub>3</sub>) δ 6.78 (s, 1H), 6.62 (d, 1H), 2.20-2.12 (m, 1H), 1.16-0.99 (comp, 3H); MS(M+1) 396.4.

**3'-(3-Hydroxy-phenyl)-1'-pentyl-1',2',3',4',5',6'-hexahydro-[2,3]bipyridinyl-5-carboxylic acid diethylamide**

<sup>1</sup>HNMR (400 MHz, CDCl<sub>3</sub>) δ 2.60-2.40 (comp, 4H), 1.41-1.10 (comp, 8H), 0.87 (t, 3H); MS(M+1) 424.3.

- 3'-(3-Hydroxy-phenyl)-1'-isobutyl-1',2',3',4',5',6'-hexahydro-[2,3]bipyridinyl-5-carboxylic acid diethylamide**

<sup>1</sup>HNMR (400 MHz, CDCl<sub>3</sub>) δ 7.58 (dd, 1H), 6.82 (s, 1H), 3.31-3.23 (comp, 2H), 1.00-0.70 (comp, 6H); MS(M+1) 410.3.

- 3'-(3-Hydroxy-phenyl)-3',4',5',6'-tetrahydro-2'H-[2,1';3',2'']terpyridine-5'-carboxylic acid diethylamide**

5           <sup>1</sup>HNMR (400 MHz, CDCl<sub>3</sub>) δ 9.02 (s, 1H), 8.29 (d, 1H), 7.39-7.34 (m, 1H), 6.87 (br, 1H); MS(M+1) 431.3.


          3'-(3-Hydroxy-phenyl)-1'-(2-methyl-butyl)-1',2',3',4',5',6'-hexahydro-  
[2,3]bipyridinyl-5-carboxylic acid diethylamide

10           <sup>1</sup>HNMR (400 MHz, CDCl<sub>3</sub>) δ 8.53-8.50 (m, 1H), 6.83 (s, 1H), 2.92-2.64 (comp, 2H),  
1.17-1.09 (comp, 3H); MS(M+1) 424.4.

5

## CLAIMS

1. A compound of the formula



wherein

- R¹ is hydrogen, (C<sub>0</sub>-C<sub>8</sub>)alkoxy-(C<sub>1</sub>-C<sub>8</sub>)alkyl-, wherein the total number of carbon atoms is eight or less, aryl, aryl-(C<sub>1</sub>-C<sub>8</sub>)alkyl-, heteroaryl, heteroaryl-(C<sub>1</sub>-C<sub>8</sub>)alkyl-, heterocyclic, heterocyclic-(C<sub>1</sub>-C<sub>8</sub>)alkyl, (C<sub>3</sub>-C<sub>7</sub>)cycloalkyl-, or (C<sub>3</sub>-C<sub>7</sub>)cycloalkyl-(C<sub>1</sub>-C<sub>8</sub>)alkyl, wherein said aryl and the aryl moiety of said aryl-(C<sub>1</sub>-C<sub>8</sub>)alkyl- are selected, independently, from phenyl and naphthyl, and wherein said heteroaryl and the heteroaryl moiety of said heteroaryl-(C<sub>1</sub>-C<sub>8</sub>)alkyl- are selected, independently, from pyrazinyl, benzofuranyl, quinolyl, isoquinolyl, benzothienyl, isobenzofuryl, pyrazolyl, indolyl, isoindolyl, benzimidazolyl, purinyl, carbazolyl, 1,2,5-thiadiazolyl, quinazolinyl, pyridazinyl, pyrazinyl, cinnolyl, phthalazinyl, quinoxalinyl, xanthinyl, hypoxanthinyl, pteridyl, 5-azacytidinyl, 5-azauracilyl, triazolopyridinyl, imidazolopyridinyl, pyrrolopyrimidinyl, pyrazolopyrimidinyl, oxazolyl, oxadiazoyl, isoxazolyl, thiazolyl, isothiazolyl, furanyl, pyrazolyl, pyrrolyl, tetrazolyl, triazolyl, thienyl, imidazolyl, pyridinyl, and pyrimidinyl; and wherein said heterocyclic and the heterocyclic moiety of said heterocyclic-(C<sub>1</sub>-C<sub>8</sub>)alkyl- are selected from saturated or unsaturated nonaromatic monocyclic or bicyclic ring systems, wherein said monocyclic ring systems contain from four to seven ring carbon atoms, from one to three of which may optionally be replaced with O, N or S, and wherein said bicyclic ring systems contain from seven to twelve ring carbon atoms, from one to four of which may optionally be replaced with O, N or S; and wherein any of the aryl, heteroaryl or heterocyclic moieties of R¹ may optionally be substituted with from one to three substituents, preferably with one or two substituents, independently selected from halo (i.e., chloro, fluoro, bromo or iodo), (C<sub>1</sub>-C<sub>6</sub>)alkyl optionally substituted with from one to seven (preferably with from zero to four) fluorine atoms, phenyl, benzyl, hydroxy, acetyl, amino, cyano, nitro, (C<sub>1</sub>-C<sub>6</sub>)alkoxy, (C<sub>1</sub>-C<sub>6</sub>)alkylamino and [(C<sub>1</sub>-C<sub>6</sub>)alkyl]<sub>2</sub>amino, and wherein any of the alkyl moieties in R¹ (e.g., the alkyl moieties of alkyl, alkoxy or alkylamino groups) may optionally be substituted with from one to seven (preferably with from zero to four) fluorine atoms;

- R² is hydrogen, aryl, heteroaryl, heterocyclic, SO<sub>2</sub>R<sup>4</sup>, COR<sup>4</sup>, CONR<sup>5</sup>R<sup>6</sup>, COOR<sup>4</sup>, or C(OH)R<sup>5</sup>R<sup>6</sup> wherein each of R<sup>4</sup>, R<sup>5</sup> and R<sup>6</sup> is defined, independently, as R¹ is defined above, or R<sup>5</sup> and R<sup>6</sup>, together with the carbon or nitrogen to which they are both attached, form a three to seven membered saturated ring containing from zero to three heterocarbons



- 5 selected, independently, from O, N and S, and wherein said aryl, heteroaryl, and heterocyclic are defined as such terms are defined above in the definition of  $R^1$ , and wherein any of the aryl, heteroaryl and heterocyclic moieties of  $R^2$  may optionally be substituted with from one to three substituents, preferably with one or two substituents, independently selected from halo (*i.e.*, chloro, fluoro, bromo or iodo),  $(C_1-C_6)$ alkyl optionally substituted with from one to seven (preferably with from zero to four) fluorine atoms, phenyl, benzyl, hydroxy, acetyl, amino, cyano, nitro,  $(C_1-C_6)$ alkoxy optionally substituted with from one to seven (preferably with from zero to four) fluorine atoms,  $(C_1-C_6)$ alkylamino and  $[(C_1-C_6)alkyl]_2$ amino;

- 15  $R^3$  is hydroxy,  $-NHSO_2R^7$ ,  $-C(OH)R^7R^8$ ,  $-OC(=O)R^7$ , fluorine or  $-CONHR^7$ , wherein  $R^7$  and  $R^8$  are the same or different and are selected from hydrogen,  $(C_1-C_4)$ alkyl,  $(C_1-C_4)$ alkoxy and  $(C_1-C_4)$ alkoxy- $(C_1-C_4)$ alkyl having a total of four or less carbon atoms, and wherein any of the alkyl moieties of  $R^7$  and  $R^8$  may optionally be substituted with from one to seven (preferably with from zero to four) fluorine atoms;


Q is oxygen or  $CH_2$ ;

X is CH or N; and


- 20  $Z^1$  and  $Z^2$  are selected, independently, from hydrogen, halo and  $(C_1-C_5)$ alkyl; with the proviso that there are no two adjacent ring oxygen atoms and no ring oxygen atom adjacent to either a ring nitrogen atom or a ring sulfur atom in any of the heterocyclic or heteroaryl moieties of formula I;

or a pharmaceutically acceptable salt of such compound.


- 25 2. A compound according to claim 1 wherein Q is  $CH_2$ .  
 3. A compound according to claim 1 wherein X is CH.  
 4. A compound according to claim 1 wherein X is N.  
 5. A compound according to claim 1 wherein Q is oxygen.  
 6. A compound according to claim 1 wherein  
 30  $R^3$  is OH,  $CONH_2$ , or fluoro.  
 7. A compound according to claim 1 wherein  
 $R^2$  is selected from  $C(OH)(C_2H_5)_2$ ,  $CONCH_3(CH_2CH_3)$ ,  $CON(C_2H_5)_2$  and the following cyclic groups:




(a)




(b)



(c)




(d)



(e)

and



(f)

- 35 8. A compound according to claim 2 wherein X is CH.  
 9. A compound according to claim 2 wherein X is N.  
 10. A compound according to claim 6 wherein Q is  $CH_2$  and X is CH.

- 5           11.     A compound according to claim 7 wherein Q is CH<sub>2</sub> and X is CH.
12.     A compound according to claim 6 wherein Q is CH<sub>2</sub> and X is N.
13.     A compound according to claim 7 wherein Q is CH<sub>2</sub> and X is N.
14.     A pharmaceutical composition for treating a disorder or condition selected from  
10     inflammatory diseases such as arthritis, psoriasis, asthma, or inflammatory bowel disease,  
disorders of respiratory function such as asthma, cough and apnea, allergies, gastrointestinal  
disorders such as gastritis, functional bowel disease, irritable bowel syndrome, functional  
diarrhoea, functional distension, functional pain, nonulcerogenic dyspepsia and other disorders of  
motility or secretion, and emesis, stroke, shock, brain edema, head trauma, spinal cord trauma,  
15     cerebral ischemia, cerebral deficits subsequent to cardiac bypass surgery and grafting,  
urogenital tract disorders such as urinary incontinence, chemical dependencies and addictions  
(e.g., addictions to or dependencies on alcohol, opiates, benzodiazepines, nicotine, heroin or  
cocaine), chronic pain, nonsomatic pain, acute pain and neurogenic pain, systemic lupus  
erythematosus, Hodgkin's disease, Sjogren's disease, epilepsy and rejection in organ transplants  
and skin grafts in a mammal, comprising an amount of a compound according to claim 1 that is  
20     effective in treating such disorder or condition and a pharmaceutically acceptable carrier.
15.     A pharmaceutical composition for treating a disorder or condition, the  
treatment or prevention of which can be effected or facilitated by modulating binding to opioid  
receptors in a mammal, comprising an amount of a compound according to claim 1 that is  
effective in treating such disorder or condition and a pharmaceutically acceptable carrier.
- 25           16.     A method for treating a disorder or condition selected from inflammatory  
diseases such as arthritis, psoriasis, asthma, or inflammatory bowel disease, disorders of  
respiratory function such as asthma, cough and apnea, allergies, gastrointestinal disorders such  
as gastritis, functional bowel disease, irritable bowel syndrome, functional diarrhoea, functional  
distension, functional pain, nonulcerogenic dyspepsia and other disorders of motility or secretion,  
30     and emesis, stroke, shock, brain edema, head trauma, spinal cord trauma, cerebral ischemia,  
cerebral deficits subsequent to cardiac bypass surgery and grafting, urogenital tract disorders  
such as urinary incontinence, chemical dependencies and addictions (e.g., addictions to or  
dependencies on alcohol, opiates, benzodiazepines, nicotine, heroin or cocaine), chronic pain,  
nonsomatic pain, acute pain and neurogenic pain, systemic lupus erythematosus, Hodgkin's  
35     disease, Sjogren's disease, epilepsy and rejection in organ transplants and skin grafts in a  
mammal, comprising administering to a mammal requiring such treatment an amount of a  
compound according to claim 1 that is effective in treating such disorder or condition.
17.     A method for treating a disorder or condition, the treatment of which can be  
40     effected or facilitated by modulating binding to opioid receptors in a mammal, comprising  
administering to a mammal requiring such treatment an amount of a compound according to  
claim 1 that is effective in treating such disorder or condition.


5           18.     A pharmaceutical composition for treating a disorder or condition selected from  
inflammatory diseases such as arthritis, psoriasis, asthma, or inflammatory bowel disease,  
disorders of respiratory function such as asthma, cough and apnea, allergies, gastrointestinal  
disorders such as gastritis, functional bowel disease, irritable bowel syndrome, functional  
10 diarrhoea, functional distension, functional pain, nonulcerogenic dyspepsia and other disorders of  
motility or secretion, and emesis, stroke, shock, brain edema, head trauma, spinal cord trauma,  
cerebral ischemia, cerebral deficits subsequent to cardiac bypass surgery and grafting,  
urogenital tract disorders such as urinary incontinence, chemical dependencies and addictions  
(e.g., addictions to or dependencies on alcohol, opiates, benzodiazepines, nicotine, heroin or  
15 cocaine), chronic pain, nonsomatic pain, acute pain and neurogenic pain, systemic lupus  
erythematosus, Hodgkin's disease, Sjogren's disease, epilepsy and rejection in organ transplants  
and skin grafts in a mammal, comprising an opioid receptor binding modulating effective amount  
of a compound according to claim 1 and a pharmaceutically acceptable carrier.

          19.     A pharmaceutical composition for treating a disorder or condition, the treatment  
or prevention of which can be effected or facilitated by modulating binding to opioid receptors in a  
20 mammal, comprising an opioid receptor binding modulating effective amount of a compound  
according to claim 1 and a pharmaceutically acceptable carrier.

          20.     A method for treating a disorder or condition selected from inflammatory  
diseases such as arthritis, psoriasis, asthma, or inflammatory bowel disease, disorders of  
respiratory function such as asthma, cough and apnea, allergies, gastrointestinal disorders such  
25 as gastritis, functional bowel disease, irritable bowel syndrome, functional diarrhoea, functional  
distension, functional pain, nonulcerogenic dyspepsia and other disorders of motility or secretion,  
and emesis, stroke, shock, brain edema, head trauma, spinal cord trauma, cerebral ischemia,  
cerebral deficits subsequent to cardiac bypass surgery and grafting, urogenital tract disorders  
such as urinary incontinence, chemical dependencies and addictions (e.g., addictions to or  
30 dependencies on alcohol, opiates, benzodiazepines, nicotine, heroin or cocaine), chronic pain,  
nonsomatic pain, acute pain and neurogenic pain, systemic lupus erythematosus, Hodgkin's  
disease, Sjogren's disease, epilepsy and rejection in organ transplants and skin grafts in a  
mammal, comprising administering to a mammal requiring such treatment an opioid receptor  
binding modulating effective amount of a compound according to claim 1.

35           21.     A method for treating a disorder or condition, the treatment or prevention of  
which can be effected or facilitated by modulating binding to opioid receptors in a mammal,  
comprising administering to a mammal requiring such treatment an opioid receptor binding  
modulating effective amount of a compound according to claim 1.

40           22.     The use of a compound of the formula



5

wherein

$R^1$  is hydrogen,  $(C_0-C_8)$ alkoxy- $(C_1-C_8)$ alkyl-, wherein the total number of carbon atoms is eight or less, aryl, aryl- $(C_1-C_8)$ alkyl-, heteroaryl, heteroaryl- $(C_1-C_8)$ alkyl-, heterocyclic, heterocyclic- $(C_1-C_8)$ alkyl,  $(C_3-C_7)$ cycloalkyl-, or  $(C_3-C_7)$ cycloalkyl- $(C_1-C_8)$ alkyl, wherein said aryl and the aryl moiety of said aryl- $(C_1-C_8)$ alkyl- are selected, independently, from phenyl and naphthyl, and wherein said heteroaryl and the heteroaryl moiety of said heteroaryl- $(C_1-C_8)$ alkyl- are selected, independently, from pyrazinyl, benzofuranyl, quinolyl, isoquinolyl, benzothienyl, isobenzofuryl, pyrazolyl, indolyl, isoindolyl, benzimidazolyl, purinyl, carbazolyl, 1,2,5-thiadiazolyl, quinazolyl, pyridazinyl, pyrazinyl, cinnolyl, phthalazinyl, quinoxalyl, xanthinyl, hypoxanthinyl, pteridyl, 5-azacytidinyl, 5-azauracil, triazolopyridinyl, imidazolopyridinyl, pyrrolopyrimidinyl, pyrazolopyrimidinyl, oxazolyl, oxadiazolyl, isoxazolyl, thiazolyl, isothiazolyl, furanyl, pyrazolyl, pyrrolyl, tetrazolyl, triazolyl, thienyl, imidazolyl, pyridinyl, and pyrimidinyl; and wherein said heterocyclic and the heterocyclic moiety of said heterocyclic- $(C_1-C_8)$ alkyl- are selected from saturated or unsaturated nonaromatic monocyclic or bicyclic ring systems, wherein said monocyclic ring systems contain from four to seven ring carbon atoms, from one to three of which may optionally be replaced with O, N or S, and wherein said bicyclic ring systems contain from seven to twelve ring carbon atoms, from one to four of which may optionally be replaced with O, N or S; and wherein any of the aryl, heteroaryl or heterocyclic moieties of  $R^1$  may optionally be substituted with from one to three substituents, preferably with one or two substituents, independently selected from halo (i.e., chloro, fluoro, bromo or iodo),  $(C_1-C_6)$ alkyl optionally substituted with from one to seven (preferably with from zero to four) fluorine atoms, phenyl, benzyl, hydroxy, acetyl, amino, cyano, nitro,  $(C_1-C_6)$ alkoxy,  $(C_1-C_6)$ alkylamino and  $[(C_1-C_6)alkyl]_2$ amino, and wherein any of the alkyl moieties in  $R^1$  (e.g., the alkyl moieties of alkyl, alkoxy or alkylamino groups) may optionally be substituted with from one to seven (preferably with from zero to four) fluorine atoms;

$R^2$  is hydrogen, aryl, heteroaryl, heterocyclic,  $SO_2R^4$ ,  $COR^4$ ,  $CONR^5R^6$ ,  $COOR^4$ , or  $C(OH)R^5R^6$  wherein each of  $R^4$ ,  $R^5$  and  $R^6$  is defined, independently, as  $R^1$  is defined above, or  $R^5$  and  $R^6$ , together with the carbon or nitrogen to which they are both attached, form a three to seven membered saturated ring containing from zero to three heterocarbons selected, independently, from O, N and S, and wherein said aryl, heteroaryl, and heterocyclic are defined as such terms are defined above in the definition of  $R^1$ , and wherein any of the aryl,

- 5 heteroaryl and heterocyclic moieties of  $R^2$  may optionally be substituted with from one to three substituents, preferably with one or two substituents, independently selected from halo (*i.e.*, chloro, fluoro, bromo or iodo),  $(C_1-C_6)$ alkyl optionally substituted with from one to seven (preferably with from zero to four) fluorine atoms, phenyl, benzyl, hydroxy, acetyl, amino, cyano, nitro,  $(C_1-C_6)$ alkoxy optionally substituted with from one to seven (preferably with from zero to
- 10 four) fluorine atoms,  $(C_1-C_6)$ alkylamino and  $[(C_1-C_6)alkyl]_2$ amino;

- $R^3$  is hydroxy,  $-NHSO_2R^7$ ,  $-C(OH)R^7R^8$ ,  $-OC(=O)R^7$ , fluorine or  $-CONHR^7$ , wherein  $R^7$  and  $R^8$  are the same or different and are selected from hydrogen,  $(C_1-C_4)$ alkyl,  $(C_1-C_4)$ alkoxy and  $(C_1-C_4)$ alkoxy- $(C_1-C_4)$ alkyl having a total of four or less carbon atoms, and wherein any of the alkyl moieties of  $R^7$  and  $R^8$  may optionally be substituted with from one to seven
- 15 (preferably with from zero to four) fluorine atoms;

Q is oxygen or  $CH_2$ ;

X is CH or N; and


$Z^1$  and  $Z^2$  are selected, independently, from hydrogen, halo and  $(C_1-C_5)$ alkyl;

- with the proviso that there are no two adjacent ring oxygen atoms and no ring oxygen
- 20 atom adjacent to either a ring nitrogen atom or a ring sulfur atom in any of the heterocyclic or heteroaryl moieties of formula I,

or a pharmaceutically acceptable salt of such compound,

for the manufacture of a medicament for a therapeutic application.

23. Use of a compound according to claim 22, wherein Q in said compound is  $CH_2$ .
- 25 24. Use of a compound according to claim 22, wherein X in said compound is CH.
25. Use of a compound according to claim 22 wherein X in said compound is N.
26. Use of a compound according to claim 22, wherein Q in said compound is oxygen.
27. Use of a compound according to claim 22 wherein  $R^3$  in said compound is OH,
- 30  $CONH_2$ , or fluoro.
28. Use of a compound according to claim 22 wherein  $R^2$  in said compound is selected from  $C(OH)(C_2H_5)_2$ ,  $CONCH_3(CH_2CH_3)$ ,  $CON(C_2H_5)_2$  and the following cyclic groups:



29. Use of a compound according to claim 23, wherein X in said compound is
- 35 CH.
30. Use of a compound according to claim 23, wherein X in said compound is N.

- 5           31.     Use of a compound according to claim 27, wherein Q in said compound is CH<sub>2</sub>, and X is CH.
32.     Use of a compound according to claim 28, wherein Q in said compound is CH<sub>2</sub>, and X is CH.
33.     Use of a compound according to claim 27, wherein Q in said compound is  
10 CH<sub>2</sub>, and X is N.
34.     Use of a compound according to claim 28, wherein Q in said compound is CH<sub>2</sub>, and X is N.
35.     Use of a compound, or a pharmaceutically acceptable salt of such compound, according to Claim 22 for the manufacture of a medicament, where the therapeutic application  
15 is treating a disorder or condition selected from inflammatory diseases such as arthritis, psoriasis, asthma, or inflammatory bowel disease, disorders of respiratory function such as asthma, cough and apnea, allergies, gastrointestinal disorders such as gastritis, functional bowel disease, irritable bowel syndrome, functional diarrhoea, functional distension, functional pain, nonulcerogenic dyspepsia and other disorders of motility or secretion, and emesis, stroke, shock,  
20 brain edema, head trauma, spinal cord trauma, cerebral ischemia, cerebral deficits subsequent to cardiac bypass surgery and grafting, urogenital tract disorders such as urinary incontinence, chemical dependencies and addictions (e.g., addictions to or dependencies on alcohol, opiates, benzodiazepines, nicotine, heroin or cocaine), chronic pain, nonsomatic pain, acute pain and neurogenic pain, systemic lupus erythematosus, Hodgkin's disease, Sjogren's disease, epilepsy  
25 and rejection in organ transplants and skin grafts in a mammal, comprising administering to a mammal requiring such treatment an amount of a compound according to claim 1 that is effective in treating such disorder or condition.
36.     Use of a compound, or a pharmaceutically acceptable salt of such compound, according to Claim 22 for the manufacture of a medicament, where the therapeutic application  
30 is treating a disorder or condition, the treatment of which can be effected or facilitated by modulating binding to opioid receptors in a mammal, comprising administering to a mammal requiring such treatment an amount of a compound according to claim 1 that is effective in treating such disorder or condition.

35

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/IB 99/01914

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 7 C07D211/34 C07D417/04 C07D401/04 C07D265/30 A61K31/445  
A61K31/426

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
IPC 7 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	KAMETANI T ET AL: "Synthesis of heterocyclic compounds. DXI. Synthesis of analgesics. XXXVI. Synthesis of 1,2,3,4,5,6-hexahydro-2,6-methano-6-phenyl-2-benzazocine" J. HETEROCYCL. CHEM. (JHCTAD);1973; VOL.10 (3); PP.291-5, XP000881100 Tohoku Univ.;Pharm. Inst.; Sendai; Japan see compounds XVII and XV, Scheme 2  -/-	1-36

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

**\* Special categories of cited documents**

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*Δ\* document member of the same patent family

Date of the actual completion of the international search

2 March 2000

Date of mailing of the international search report

24.03.00

Name and mailing address of the ISA  
European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Scruton-Evans, I

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/IB 99/01914

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	KAMETANI T ET AL: "Syntheses of heterocyclic compounds. DLXXIV. Syntheses of analgetics. XL. Synthesis of 1-substituted 3-(3-hydroxyphenyl)-3-phenylpiperidines" YAKUGAKU ZASSHI (YKKZAJ);1974; VOL.94 (11); PP.1489-90, XP000872486 Tohoku Univ.;Pharm. Inst.; Sendai; Japan see compound 3,3a and 3b and abstract	1-3,6,8, 10, 14-24, 27,29, 31,35,36
Y	FOSCOLOS G B ET AL: "Diarylmorpholines - cyclic analogs of diphenhydramine" CHEM. CHRON. (CMCRCZ,0366693X);1989; VOL.18 (1); PP.59-70, XP000881242 Univ. Athens;Lab. Pharm. Chim.; Athens; GR-106 80; Greece (GR) see compounds of formula 5, Tables III,VI and VII	1-36
P,A	THOMAS J B ET AL: "(.+-)-4-(N-allyl-cis-3-methyl-4-piperidinyl)phenylamino!-N,N-diet hylbenzamide displays selective binding for the delta opioid receptor" BIOORG. MED. CHEM. LETT. (BMCLE8,0960894X);1999; VOL.9 (20); PP.3053-3056, XP002132038 Research Triangle Institute;Chemistry and Life Sciences; Research Triangle Park; 27709; NC; USA (US) see compounds of formula 3 and whole document	1-36
Y	CHEMICAL ABSTRACTS, vol. 083, no. 25, 22 December 1975 (1975-12-22) Columbus, Ohio, US; abstract no. 206126, KAMETANI T: "2-Benzazocines" XP002132039 abstract & JP 50 041895 - (SENDAI FUKUSOKAN KAGAKU KENKYUSHO;JAPAN) see compounds of formula II	1-36
A	US 4 816 586 A (PORTOGHESE PHILIP S) 28 March 1989 (1989-03-28) cited in the application the whole document	1-36
A	WO 98 52929 A (PFIZER LTD ;MAW GRAHAM NIGEL (GB); PFIZER (US)) 26 November 1998 (1998-11-26) the whole document	1-36



# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/IB 99/01914

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
Although claims 16,17,20,21 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6 4(a)

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/IB 99/01914

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
JP 50041895 -		NONE	
US 4816586 A	28-03-1989	WO 8900995 A	09-02-1989
WO 9852929 A	26-11-1998	AU 7644998 A	11-12-1998
		HR 980267 A	28-02-1999

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**